Agenda item 3  
  
ETANERCEPT  
50 mg in 1 mL single use pre-filled syringes, 4, 1 pack  
Injection 50 mg in 1 mL single use auto-injector, 4, 1 pack  
Brenzys  
Merck, Sharp & Dohme

1. Purpose of Item
   1. Changes to the initial 2 and continuing treatment restrictions for the etanercept biosimilar, Brenzys, to Authority Required (STREAMLINED) were requested.
   2. The submission also requested a change to the prescribing software to give preference to Brenzys for patients naïve to treatment with etanercept.
   3. The Minister (delegate) requested that the PBAC provide advice under section 101(3) of the *National Health Act, 1953* (the Act) as to whether there would be any clinical or other concerns about appropriate use of medicines if a policy decision were made to apply the biosimilar uptake measures agreed as part of the strategic agreement with Medicines Australia to etanercept.
2. Background

## Etanercept

* 1. The PBAC recommended the listing of Brenzys, a biosimilar brand of etanercept, at its July 2016 meeting for severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis, and severe chronic plaque psoriasis. At the same meeting, the PBAC also advised the Minister that it considered the Enbrel and Brenzys brands of etanercept could be marked as equivalent in the Schedule of Pharmaceutical Benefits (’a’ flagged) for the purposes of substitution by the pharmacist at the point of dispensing for all the circumstances for which both brands are listed.
  2. In the pre-PBAC response relating to the submission to the July 2016 meeting, the sponsor requested that Brenzys be listed as an Authority Required (streamlined) listing, while Enbrel remained an Authority required (in writing). However, the PBAC did not consider that this would be appropriate because of the risk of leakage into less severe disease.

## Biosimilar uptake measures

* 1. As part of the 2017-18 budget, the Government entered into a Strategic Agreement with Medicines Australia and further agreement with the Generic and Biosimilar Medicines Association. Part of these agreements was to introduce biosimilar uptake drivers. Two biosimilar uptake drivers identified were to:
  + Allow a lower level of authority for the biosimilar than the reference biological agent at commencement and/or continuation of therapy; and
  + Identify the biosimilar brand as the preferred choice for treatment naïve patients.
  1. With respect to these uptake measures, the PBAC will be requested to provide case by case advice as to whether there would be any clinical or other concerns about appropriate use of medicines if a policy decision were made to apply the uptake measures mentioned above.


1. Requested advice
   1. The submission requested all Brenzys initial 2 (change or recommencement of therapy) and continuing restrictions be changed to Authority Required (streamlined), and that a ‘note’ be included in all initial 1 (new patient or recommencement of treatment) restrictions to indicate that the biosimilar brand is the preferred choice for patients initiating treatment with etanercept. The requested changes to the authority category are illustrated below.



**Figure 1. Etanercept authorities as proposed in the submission.** Purple boxes indicate the sponsor’s proposed Authority Required (STREAMLINED) restrictions; blue boxes indicate proposed Authority required (written) restrictions (as per current restrictions).

* 1. The submission claimed that retaining an Authority required (in writing) for the initial 1 restriction would address potential use outside the intended PBS population.
  2. The PBAC noted that:
  + The proposed change to the continuing treatment restriction to Authority Required (streamlined) did not require patients to provide evidence of response in order to access ongoing treatment, although evidence could be documented in the patient’s medical records.
  + The PBAC further noted that if the change of treatment/re-commencement of treatment restriction was changed to Authority required (streamlined) and future biosimilar biological agents have the same restrictions applied, then patients would be able to change biological agents without ever needing to provide evidence of response (although that evidence could be documented in the patients’ medical records).
  + The PBAC noted that under the current restrictions if evidence of ongoing response is not provided then the patient is deemed to have failed treatment and that there are limits on the number of treatments that a patient can trial for each condition. The PBAC noted that if the continuing restrictions for biosimilar biological agents were changed to Authority Required (streamlined) then the Department of Human Services (DHS) would not receive evidence to demonstrate response to treatment (or failure to achieve a response to treatment) and hence would be unable to administer a subsidy of a set number of treatment failures for a condition.

3.4 An alternative option for reducing the category of authority for Brenzys was proposed by the Secretariat of changing second and subsequent continuing treatment to an Authority required (streamlined) listing. Under this proposal, the initial and first continuing restrictions remain Authority required (in writing) and evidence of response would only be provided for the first continuing treatment. This proposal is illustrated in Figure 2 below.



**Figure 2. Alternative approach to streamlined authorities for etanercept.** Purple boxes indicate proposed Authority Required (STREAMLINED) restrictions; blue boxes indicate proposed Authority required (in writing) restrictions (as per the current restrictions).

* 1. The PBAC noted that under this option the DHS will not receive evidence of treatment failure (inadequate ongoing response to treatment) if treatment failure occurs at the second or subsequent continuing stage.

*For more detail on PBAC’s view, see section “PBAC outcome”*

1. PBAC outcome
   1. The PBAC advised that there would not be clinical or other concerns about appropriate use of medicines if a policy decision were made to lower the authority requirement for only the biosimilar brand of etanercept if this were done taking into account the recommendations below.
   2. The PBAC recommended that all initial treatment restrictions for etanercept, including those for new patients, patients changing treatment and recommencing treatment, remain as Authority required (in writing) listings. The PBAC affirmed this in relation to the listings for etanercept for the treatment of severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis and severe chronic plaque psoriasis.
   3. The PBAC recommended that the continuing restrictions for etanercept for the above noted conditions could be split into first continuing and subsequent continuing restrictions. The PBAC recommended that the first continuing restrictions be Authority required (in writing) restrictions retaining the response to treatment criteria that currently exists in the continuing restrictions. The PBAC recommended that the subsequent continuing restrictions be Authority Required (streamlined) restrictions.
   4. The PBAC recommended that subsequent continuing restrictions for etanercept retain the requirement for patients to be responding to treatment, but noted that being an Authority required (streamlined) listing, no evidence of response would be provided to the Department of Human Services (DHS) at the time of prescribing; rather that ongoing treatment response would be documented in the patient’s medical notes. The PBAC further noted that the DHS would no longer receive any information as to whether the patient continued to respond to treatment beyond the response demonstrated under the first continuing restriction criteria. The PBAC noted that in practice this will mean that the DHS will no longer be able to determine if a patient has failed treatment with etanercept (for the conditions for which these recommendations are applied) unless failure to respond to treatment occurs at the first continuing authority application time point. If failure to respond to treatment occurs whilst on subsequent continuing treatment then the DHS will no longer have a record of this. The PBAC further noted that in administering these restrictions this will mean the DHS will no longer have the full history of patients’ treatment failures and hence that compliance with the number of treatment failures allowed under each of the conditions for which etanercept is listed will rely on the prescriber providing the complete history of prior biological agent therapies and associated treatment failures for the condition.
   5. Noting that biological agent medicines for the treatment of severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis and severe chronic plaque psoriasis have been subsided via the PBS for a number of years, the PBAC considered that this lower category of authority for etanercept’s subsequent continuing restrictions and the implications for the overall administration of the restrictions for these conditions should not substantially change the utilisation of these medicines.
   6. The PBAC also noted that the connection of data for initiation and continuation of treatment and subsequent continuation of treatment at the patient level would no longer be complete in DHS’s authority database. However, the PBAC noted that patient identification numbers (PINs) were available within DHS prescriptions data to undertake patient level analyses on the length of treatment on etanercept for the indications to which these changes have been applied.
   7. The PBAC noted that there will be a number of changes required to the restriction wording for etanercept across all treatment phases (the current initial, change, recommencement and continuing restrictions and associated notes) to accommodate these changes.
   8. The PBAC did not recommend lowering the category of authority for the initial 2 and continuing restrictions for etanercept as proposed by the sponsor as it considered that changing the restrictions for these treatment phases to Authority required (streamlined) was likely to result in use outside the intended PBS population to a wider population, such as patients who do not demonstrate the extent of response required for continuing treatment and use in patients with less severe disease. The PBAC noted that such extended use would likely affect the cost effectiveness of etanercept and represent use that is not consistent with the evidence of effectiveness considered by the PBAC when recommending listing on the PBS of etanercept for severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis and severe chronic plaque psoriasis.
   9. The PBAC noted the request for a change to the PBS Schedule and prescribing software to give preference to the biosimilar brand of etanercept for patients naïve to treatment with etanercept. The PBAC noted that this is a matter for Government, however it did not have any concerns about encouraging prescribing of a biosimilar brand rather than the reference biological agent brand for treatment naïve patients, including through notes in the Schedule and prescribing software changes.

## Outcome

Recommended

1. Recommended listing
   1. Change existing listings as follows. Changes to the existing listings are highlighted in bolded italics and strikethrough. Restrictions have been grouped by indication.

## Rheumatoid arthritis

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9459W* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9089J* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel  *8637N* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe active rheumatoid arthritis | | | | | |
| **PBS Indication:** | Severe active rheumatoid arthritis | | | | | |
| **Treatment phase:** | Initial 1 (new patient or patient recommencing treatment after a break of more than 24 months) | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist;  OR  Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. | | | | | |
| **Clinical criteria:** | ~~Patient must have severe active rheumatoid arthritis,~~  ~~AND~~  Patient must have received no PBS-subsidised treatment with a disease modifying anti-rheumatic drug (bDMARD) for this condition in the previous 24 months,  AND  Patient must not have failed previous PBS-subsidised treatment with this drug for this condition, and have not already failed, or ceased to respond to, PBS-subsidised bDMARD treatment for this condition 5 times,  AND  Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily;  OR  Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily;  OR  Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if 3 or more of methotrexate, hydroxychloroquine, leflunomide and sulfasalazine are contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above, must include at least 3 months continuous treatment with each of at least 2 DMARDs, with one or more of the following DMARDs being used in place of the DMARDS which are contraindicated or not tolerated: (i) azathioprine at a dose of at least 1 mg/kg per day; and/or (ii) cyclosporin at a dose of at least 2 mg/kg/day; and/or (iii) sodium aurothiomalate at a dose of 50 mg weekly,  AND  Patient must not receive more than 16 weeks of treatment under this restriction. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction bDMARD means abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab or tofacitinib.  If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose, the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.  The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity.  The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.  If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form; and  (3) a signed patient acknowledgement.  Assessment of a patient's response to an initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.  Applications for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.  Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be submitted no later than 4 weeks from the date that course was ceased.  Where the most recent course of PBS-subsidised treatment with this drug was approved under the ***first*** continuing ***or subsequent continuing*** treatment criteria, the patient must have been assessed for response~~, and the assessment must be submitted no later than 4 weeks from the date that course was ceased~~.  If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.  The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either  (a) a total active joint count of at least 20 active (swollen and tender) joints; or  (b) at least 4 active joints from the following list of major joints:  (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or  (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).  The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.  If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.  Where the baseline joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP is provided with the initial application, the same marker will be used to determine response. | | | | | |
| ***Administrative Advice*** | ***Biosimilar policy***  *Prescribing of the biosimilar brand Brenzys is encouraged for treatment naïve patients.*  *Encouraging biosimilar prescribing for treatment naïve patients is Government policy. A viable biosimilar market is expected to result in reduced costs for biological medicines, allowing the Government to reinvest in new treatments. Further information can be found on the Biosimilar Awareness Initiative webpage (*[*www.health.gov.au/biosimilars*](http://www.health.gov.au/biosimilars)*).* | | | | | |
| ***Administrative Advice*** | *No increase in the maximum quantity or number of units may be authorised.*  *No increase in the maximum number of repeats may be authorised.* | | | | | |
| **Administrative Advice** | The Department of Human Services website (www.humanservices.gov.au) has details of the toxicities, including severity, which will be accepted for the following purposes:  (a) exempting a patient from the requirement to undertake a minimum 3 month trial of methotrexate at a 20 mg weekly dose;  (b) substituting azathioprine, cyclosporin or sodium aurothiomalate for another DMARD as part of the 6 month intensive DMARD trial;  (c) exempting a patient from the requirement for a 6 month trial of intensive DMARD therapy.  Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative Advice** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying antirheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab), the T-cell co-stimulation modulator (abatacept) and the Janus-associated kinase (JAK) inhibitor (tofacitinib).    Patients are eligible for PBS-subsidised treatment with only 1 of the above disease modifying anti-rheumatic drugs at any 1 time.  In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.  A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:  - a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,  - a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and  - once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.  For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact the Department of Human Services on 1800 700 270. A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.  (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or  (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).  Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6-month intensive DMARD trial, but prior to ceasing DMARD therapy.  Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab, tocilizumab and tofacitinib, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.  A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to the Department of Human Services within 4 weeks.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD. For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where required*** an application is submitted to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course.  Abatacept patients:  Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription ~~for the pre-filled syringes~~, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.  Rituximab patients:  A further application may be submitted to the Department of Human Services 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.  (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response. It is recommended that a patient be reviewed the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  ***~~Where required,~~*** ~~Aassessments of response to a course of PBS-subsidised therapy must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.~~  Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  (2) Swapping therapy  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.  Abatacept ~~patients~~:  Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.  ***Rituximab:***  In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological agent therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and the Department of Human Services will assess response according to these revised baseline measurements.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequentcontinuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.  Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe active rheumatoid arthritis | | | | | |
| **PBS Indication:** | Severe active rheumatoid arthritis | | | | | |
| **Treatment phase:** | Initial treatment - Initial 2 (change or re-commencement of treatment after break of less than 24 months) | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist;  OR  Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. | | | | | |
| **Clinical criteria:** | ~~Patient must have a documented history of severe active rheumatoid arthritis,~~  ~~AND~~  Patient must have received prior PBS-subsidised biological disease modifying anti-rheumatic drug (bDMARD) treatment for this condition and are eligible to receive further bDMARD therapy,  AND  Patient must not receive more than 16 weeks of treatment under this restriction. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction bDMARD means abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab or tofacitinib.  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.  Applications for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.  Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the initial 1 or 2 treatment restrictions, the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must be submitted no later than 4 weeks from the date that course was ceased.  Where the most recent course of PBS-subsidised treatment with this drug was approved under the ***first*** continuing ***or subsequent continuing*** treatment criteria, the patient must have been assessed for response~~, and the assessment must be submitted no later than 4 weeks from the date that course was ceased~~.  Where a response assessment is not undertaken ~~and submitted within these timeframes~~, the patient will be deemed to have failed to respond to treatment with this drug.  If a patient fails to demonstrate a response to a treatment with this drug under this restriction ***they*** will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.  A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD.  An adequate response to treatment is defined as:  An ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (b) a reduction in the number of the following active joints, from at least 4, by at least 50%:  (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or  (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). | | | | | |
| ***Administrative Advice:*** | *No increase in the maximum quantity or number of units may be authorised.*  *No increase in the maximum number of repeats may be authorised.* | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying antirheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab), the T-cell co-stimulation modulator (abatacept) and the Janus-associated kinase (JAK) inhibitor (tofacitinib).    Patients are eligible for PBS-subsidised treatment with only 1 of the above disease modifying anti-rheumatic drugs at any 1 time.  In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.  A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:  - a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,  - a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and  - once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.  For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact the Department of Human Services on 1800 700 270. A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.  (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or  (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).  Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6-month intensive DMARD trial, but prior to ceasing DMARD therapy.  Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab, tocilizumab and tofacitinib, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.  A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to the Department of Human Services within 4 weeks.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD. For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where required*** an application is submitted to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course.  Abatacept patients:  Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription ~~for the pre-filled syringes~~, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.  Rituximab patients:  A further application may be submitted to the Department of Human Services 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.  (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response. It is recommended that a patient be reviewed the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  ***~~Where required,~~*** ~~Aassessments of response to a course of PBS-subsidised therapy must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.~~  Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  (2) Swapping therapy  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.  Abatacept ~~patients~~:  Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.  ***Rituximab:***  In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological agent therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and the Department of Human Services will assess response according to these revised baseline measurements.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequentcontinuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.  Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe active rheumatoid arthritis | | | | | |
| **PBS Indication:** | Severe active rheumatoid arthritis | | | | | |
| **Treatment phase:** | Initial treatment - Initial 1 (new patient or patient recommencing treatment after a break of more than 24 months) or Initial 2 (change or recommencement of treatment after break of less than 24 months) – balance of supply. | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing  Authority Required - Telephone | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist;  OR  Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. | | | | | |
| **Clinical criteria:** | Patient must have received insufficient therapy with this drug ***for this condition*** under the Initial 1 (new patient or patient recommencing treatment after break of more than 24 months) restriction to complete 16 weeks treatment;  OR  Patient must have received insufficient therapy with this drug ***for this condition*** under the Initial 2 (change or recommencement of treatment after break of less than 24 months) restriction to complete 16 weeks treatment,  AND  The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| ***Administrative Advice:*** | *No increase in the maximum quantity or number of units may be authorised.*  *No increase in the maximum number of repeats may be authorised.* | | | | | |
| **Administrative Advice:** | Authority approval for sufficient therapy to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Written application for authority approval for sufficient therapy to complete a maximum of 16 weeks of treatment should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying antirheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab), the T-cell co-stimulation modulator (abatacept) and the Janus-associated kinase (JAK) inhibitor (tofacitinib).    Patients are eligible for PBS-subsidised treatment with only 1 of the above disease modifying anti-rheumatic drugs at any 1 time.  In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.  A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:  - a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,  - a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and  - once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.  For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact the Department of Human Services on 1800 700 270. A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.  (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or  (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).  Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6-month intensive DMARD trial, but prior to ceasing DMARD therapy.  Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab, tocilizumab and tofacitinib, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.  A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to the Department of Human Services within 4 weeks.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD. For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where required*** an application is submitted to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course.  Abatacept patients:  Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription ~~for the~~ ~~pre-filled syringes~~, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.  Rituximab patients:  A further application may be submitted to the Department of Human Services 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.  (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response. It is recommended that a patient be reviewed the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  ***~~Where required,~~*** ~~Aassessments of response to a course of PBS-subsidised therapy must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.~~  Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  (2) Swapping therapy  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.  Abatacept ~~patients~~:  Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.  ***Rituximab:***  In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological agent therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and the Department of Human Services will assess response according to these revised baseline measurements.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequentcontinuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.  Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9460X* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9090K* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *8638P* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe active rheumatoid arthritis | | | | | |
| **PBS Indication:** | Severe active rheumatoid arthritis | | | | | |
| **Treatment phase:** | ***First*** Continuing treatment | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist;  OR  Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. | | | | | |
| **Clinical criteria:** | ~~Patient must have a documented history of severe active rheumatoid arthritis,~~  ~~AND~~  Patient must have demonstrated an adequate response to treatment with this drug,  AND  Patient must have received this drug as their most recent course of PBS-subsidised biological disease modifying anti-rheumatic drug (bDMARD) treatment *for this condition*;  AND  Patient must not receive more than 24 weeks of treatment ~~per continuing treatment course authorised~~ under this restriction. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction bDMARD means abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab or tofacitinib.  An adequate response to treatment is defined as:  an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;  AND either of the following:  (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (b) a reduction in the number of the following active joints, from at least 4, by at least 50%:  (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or  (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).  Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.  ~~All the applications for continuing treatment with this drug must include a measurement of response to the prior course of therapy~~. ~~This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.~~ ~~If the application is t~~***~~T~~***he ~~first~~ application for ***first*** continuing treatment with this drug~~, it~~ must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with an initial treatment course. ***This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.***  Where a response assessment is not undertaken and submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.  If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. | | | | | |
| ***Administrative Advice:*** | *Note No increase in the maximum quantity or number of units may be authorised.*  *Note No increase in the maximum number of repeats may be authorised.* | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying antirheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab), the T-cell co-stimulation modulator (abatacept) and the Janus-associated kinase (JAK) inhibitor (tofacitinib).    Patients are eligible for PBS-subsidised treatment with only 1 of the above disease modifying anti-rheumatic drugs at any 1 time.  In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.  A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:  - a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,  - a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and  - once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.  For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact the Department of Human Services on 1800 700 270. A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.  (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or  (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).  Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6-month intensive DMARD trial, but prior to ceasing DMARD therapy.  Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab, tocilizumab and tofacitinib, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.  A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to the Department of Human Services within 4 weeks.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD. For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where required*** an application is submitted to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course.  Abatacept patients:  Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription ~~for the~~ ~~pre-filled syringes~~, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.  Rituximab patients:  A further application may be submitted to the Department of Human Services 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.  (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response. It is recommended that a patient be reviewed the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  ***~~Where required,~~*** ~~Aassessments of response to a course of PBS-subsidised therapy must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.~~  Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  (2) Swapping therapy  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.  Abatacept ~~patients~~:  Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.  ***Rituximab:***  In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological agent therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and the Department of Human Services will assess response according to these revised baseline measurements.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequentcontinuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.  Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. | | | | | |

#### Subsequent continuing restriction – version one. This restriction is used where the subsequent continuing restriction is Authority Required (streamlined)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel | PF |
|  | | | | | | |
| ***Category /***  ***Program*** | *GENERAL – General Schedule (Code GE)* | | | | | |
| ***Prescriber type:*** | *Medical Practitioners* | | | | | |
| ***Condition:*** | *Severe active rheumatoid arthritis* | | | | | |
| ***PBS Indication:*** | *Severe active rheumatoid arthritis* | | | | | |
| ***Treatment phase:*** | *Subsequent continuing treatment* | | | | | |
| ***Restriction Level / Method:*** | *Authority Required - Streamlined* | | | | | |
| ***Treatment criteria:*** | *Must be treated by a rheumatologist;*  *OR*  *Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis.* | | | | | |
| ***Clinical criteria:*** | *Patient must have demonstrated an adequate response to treatment with this drug*  *AND*  *Patient must have received this drug as their most recent course of biological disease modifying anti-rheumatic drug (bDMARD) treatment for this condition;*  *AND*  *Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course under this restriction.* | | | | | |
| ***Population criteria:*** | *Patient must be aged 18 years or older.* | | | | | |
| ***Prescriber Instructions:*** | *For the purposes of this restriction bDMARD means abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab or tofacitinib.*  *An adequate response to treatment is defined as:*  *an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;*  *AND either of the following:*  *(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or*  *(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:*  *(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*  *(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*  *Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.*  ***The measurement of response to the prior course of therapy must be documented in the patient’s medical notes.***  *If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.* | | | | | |
| ***Administrative Advice:*** | *Note No increase in the maximum quantity or number of units may be authorised.*  *Note No increase in the maximum number of repeats may be authorised.* | | | | | |
| ***Administrative Advice:*** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying antirheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab), the T-cell co-stimulation modulator (abatacept) and the Janus-associated kinase (JAK) inhibitor (tofacitinib).    Patients are eligible for PBS-subsidised treatment with only 1 of the above disease modifying anti-rheumatic drugs at any 1 time.  In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.  A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:  - a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,  - a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and  - once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.  For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact the Department of Human Services on 1800 700 270. A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.  (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or  (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).  Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6-month intensive DMARD trial, but prior to ceasing DMARD therapy.  Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab, tocilizumab and tofacitinib, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.  A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to the Department of Human Services within 4 weeks.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD. For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where required*** an application is submitted to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course.  Abatacept patients:  Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription ~~for the~~ ~~pre-filled syringes~~, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.  Rituximab patients:  A further application may be submitted to the Department of Human Services 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.  (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response. It is recommended that a patient be reviewed the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  ***~~Where required,~~*** ~~Aassessments of response to a course of PBS-subsidised therapy must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.~~  Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  (2) Swapping therapy  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.  Abatacept ~~patients~~:  Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.  ***Rituximab:***  In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological agent therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and the Department of Human Services will assess response according to these revised baseline measurements.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequentcontinuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.  Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. | | | | | |

#### Subsequent continuing restriction – version two. This restriction is used where the subsequent continuing restriction is Authority Required (in writing).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel | PF |
|  | | | | | | |
| ***Category /***  ***Program*** | *GENERAL – General Schedule (Code GE)* | | | | | |
| ***Prescriber type:*** | *Medical Practitioners* | | | | | |
| ***Condition:*** | *Severe active rheumatoid arthritis* | | | | | |
| ***PBS Indication:*** | *Severe active rheumatoid arthritis* | | | | | |
| ***Treatment phase:*** | *Subsequent continuing treatment* | | | | | |
| ***Restriction Level / Method:*** | *Authority Required - In Writing* | | | | | |
| ***Treatment criteria:*** | *Must be treated by a rheumatologist;*  *OR*  *Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis.* | | | | | |
| ***Clinical criteria:*** | *Patient must have demonstrated an adequate response to treatment with this drug;*  *AND*  *Patient must have received this drug as their most recent course of PBS-subsidised biological disease modifying anti-rheumatic drug (bDMARD) treatment for this condition;*  *AND*  *Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction.* | | | | | |
| ***Population criteria:*** | *Patient must be aged 18 years or older.* | | | | | |
| ***Prescriber Instructions:*** | *For the purposes of this restriction bDMARD means abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab or tofacitinib.*  *An adequate response to treatment is defined as:*  *an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline;*  *AND either of the following:*  *(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or*  *(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:*  *(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*  *(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*  *Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response.*  *The authority application must be made in writing and must include:*  *(1) a completed authority prescription form; and*  *(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.*  *All applications for subsequent continuing treatment with this product must include a measurement of response to the prior course of therapy. ~~This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.~~*  *Where a response assessment is not undertaken ~~and submitted within these timeframes,~~ the patient will be deemed to have failed to respond to treatment with this drug.*  *If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.* | | | | | |
| ***Administrative Advice:*** | *Note No increase in the maximum quantity or number of units may be authorised.*  *Note No increase in the maximum number of repeats may be authorised.* | | | | | |
| ***Administrative Advice:*** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
|  | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying antirheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab), the T-cell co-stimulation modulator (abatacept) and the Janus-associated kinase (JAK) inhibitor (tofacitinib).    Patients are eligible for PBS-subsidised treatment with only 1 of the above disease modifying anti-rheumatic drugs at any 1 time.  In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.  A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:  - a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,  - a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and  - once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.  For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact the Department of Human Services on 1800 700 270. A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.  (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or  (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).  Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6-month intensive DMARD trial, but prior to ceasing DMARD therapy.  Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab, tocilizumab and tofacitinib, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.  A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to the Department of Human Services within 4 weeks.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD. For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where required*** an application is submitted to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course.  Abatacept patients:  Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription ~~for the~~ ~~pre-filled syringes~~, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.  Rituximab patients:  A further application may be submitted to the Department of Human Services 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.  (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response. It is recommended that a patient be reviewed the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  ***~~Where required,~~*** ~~Aassessments of response to a course of PBS-subsidised therapy must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.~~  Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  (2) Swapping therapy  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.  Abatacept ~~patients~~:  Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.  ***Rituximab:***  In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological agent therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and the Department of Human Services will assess response according to these revised baseline measurements.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequentcontinuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.  Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe active rheumatoid arthritis | | | | | |
| **PBS Indication:** | Severe active rheumatoid arthritis | | | | | |
| **Treatment phase:** | Continuing treatment – balance of supply | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing  Authority Required - Telephone | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist;  OR  Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis. | | | | | |
| **Clinical criteria:** | Patient must have received insufficient therapy with this drug ***for this condition*** under the ***first* c**ontinuing treatment restriction to complete 24 weeks treatment;  ***OR***  ***Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment;***  AND  The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction***s***. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| ***Administrative Advice:*** | *Note No increase in the maximum quantity or number of units may be authorised.*  *Note No increase in the maximum number of repeats may be authorised.* | | | | | |
| **Administrative Advice:** | Authority approval for sufficient therapy to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Written application for authority approval for sufficient therapy to complete a maximum of 24 weeks of treatment should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying antirheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab), the T-cell co-stimulation modulator (abatacept) and the Janus-associated kinase (JAK) inhibitor (tofacitinib).    Patients are eligible for PBS-subsidised treatment with only 1 of the above disease modifying anti-rheumatic drugs at any 1 time.  In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.  A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:  - a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,  - a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and  - once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.  For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact the Department of Human Services on 1800 700 270. A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.  (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or  (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).  Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6-month intensive DMARD trial, but prior to ceasing DMARD therapy.  Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab, tocilizumab and tofacitinib, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.  A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to the Department of Human Services within 4 weeks.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD. For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where required*** an application is submitted to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course.  Abatacept patients:  Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription ~~for the~~ ~~pre-filled syringes~~, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.  Rituximab patients:  A further application may be submitted to the Department of Human Services 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.  (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response. It is recommended that a patient be reviewed the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  ***~~Where required,~~*** ~~Aassessments of response to a course of PBS-subsidised therapy must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.~~  Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  (2) Swapping therapy  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.  Abatacept ~~patients~~:  Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.  ***Rituximab:***  In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological agent therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and the Department of Human Services will assess response according to these revised baseline measurements.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequentcontinuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.  Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. | | | | | |

## Flow-on changes to restrictions

*The changes to the note associated with the PBS listings for the medicines for the treatment of severe active rheumatoid arthritis in adults (as below) apply to all other medicines listed for this indication. At the time of the August 2017 PBAC Special meeting this included abatacept, adalimumab, certolizumab, golimumab, infliximab, rituximab, tocilizumab and tofacitinib.*

|  |  |
| --- | --- |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological disease modifying antirheumatic drugs (bDMARDs) for adults with severe active rheumatoid arthritis. Where the term bDMARD appears in the following notes and restrictions it refers to the tumour necrosis factor (TNF) alfa antagonists (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), the chimeric anti-CD20 monoclonal antibody (rituximab), the interleukin-6 inhibitor (tocilizumab), the T-cell co-stimulation modulator (abatacept) and the Janus-associated kinase (JAK) inhibitor (tofacitinib).    Patients are eligible for PBS-subsidised treatment with only 1 of the above disease modifying anti-rheumatic drugs at any 1 time.  In order to be eligible to receive PBS-subsidised treatment with rituximab, a patient must have already failed to demonstrate a response to at least 1 course of treatment with a PBS-subsidised TNF-alfa antagonist.  A patient receiving PBS-subsidised bDMARD therapy may swap to an alternate bDMARD without having to experience a disease flare. Under these interchangeability arrangements:  - a patient may continue to receive long-term treatment with a PBS-subsidised bDMARD while they continue to show a response to therapy,  - a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once, and  - once a patient has either failed or ceased to respond to treatment 5 times, they will not be eligible to receive further PBS-subsidised bDMARDs for the treatment of rheumatoid arthritis.  For patients who have failed PBS-subsidised treatment with 2 or 3 TNF-alfa antagonists prior to 1 August 2010 please contact the Department of Human Services on 1800 700 270. A patient whose most recent course of PBS-subsidised therapy was with rituximab and whose response to this treatment is sustained for more than 12 months, may apply for a further course of rituximab under the Continuing treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has a break in therapy of less than 24 months may commence a further course of treatment with a bDMARD without having to requalify under the Initial 1 treatment restriction. A patient who has failed fewer than 5 bDMARDs and who has had a break in therapy of longer than 24 months must requalify for treatment under the Initial 1 treatment restriction. The length of a treatment break is measured from the date the most recent treatment with PBS-subsidised bDMARD treatment is stopped to the date of the new application for treatment with a bDMARD.  (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment and wishes to commence such therapy, excluding rituximab (Initial 1); or  (ii) a patient wishes to re-commence treatment with a bDMARD following a break in PBS-subsidised therapy of more than 24 months (Initial 1); or  (iii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iv) a patient wishes to re-commence treatment with a specific bDMARD following a break of less than 24 months in PBS-subsidised therapy with that agent (Initial 2).  Initial applications for new or re-commencing patients (Initial 1) must include a joint count and ESR and/or CRP measured at the completion of the 6-month intensive DMARD trial, but prior to ceasing DMARD therapy.  Initial treatment authorisations will be limited to provide a maximum of 16 weeks of therapy for abatacept, adalimumab, etanercept, golimumab, tocilizumab and tofacitinib, 18 to 20 weeks of therapy with certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab and 2 infusions of rituximab.  A patient must be assessed for response to any course of initial PBS-subsidised treatment (excluding rituximab) following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Rituximab patients must be assessed following a minimum of 12 weeks after the first infusion, and this assessment must be submitted to the Department of Human Services within 4 weeks.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD. For second and subsequent courses of PBS-subsidised bDMARD (excluding rituximab) treatment it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where required*** an application is submitted to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course.  Abatacept patients:  Patients are eligible to receive one I.V. loading dose when commencing treatment with the subcutaneous formulation. For these patients two prescriptions are required, the first prescription for the I.V. loading dose for sufficient vials for one dose based on the patient's weight with no repeats. The second prescription ~~for the pre-filled syringes~~, with a maximum quantity of 4 and up to 3 repeats, must be submitted with the initial application.  Rituximab patients:  A further application may be submitted to the Department of Human Services 24 weeks after the first infusion. New baselines may be submitted with this application if appropriate.  (b) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD (excluding rituximab), a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response. It is recommended that a patient be reviewed the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  ***~~Where required,~~*** ~~Aassessments of response to a course of PBS-subsidised therapy must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.~~  Rituximab patients:  A patient may qualify to receive a further course of treatment (every 24 weeks) with this agent providing they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with rituximab. The patient remains eligible to receive a course of rituximab every 24 weeks providing they continue to demonstrate a response as specified in the restriction. Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  (2) Swapping therapy  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the joint count) or the prior non-bDMARD therapy requirements, except if the patient has had a break in therapy of more than 24 months. However the requirement for concomitant treatment with methotrexate, where it applies, must be met for each bDMARD trialled.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug.  Abatacept ~~patients~~:  Patients swapping from I.V. abatacept to subcutaneous abatacept will not be eligible for an I.V. loading dose when commencing treatment with the subcutaneous formulation.  ***Rituximab:***  In order to trial rituximab, a patient must have trialled and failed to demonstrate a response to at least 1 PBS-subsidised TNF-alfa antagonist treatment.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  PBS subsidy does not allow for patients to receive treatment with another PBS-subsidised biological agent during the required treatment-free period applying to patients who have demonstrated a response to their most recent course of rituximab. This means that patients who have demonstrated a response to a course of rituximab must have a PBS-subsidised biological agent therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate bDMARD. Patients who fail to respond to rituximab and who qualify and wish to trial a course of an alternate bDMARD may do so without having to have any treatment-free period.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the joint count, ESR and/or CRP submitted with the first authority application for a bDMARD. However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted and the Department of Human Services will assess response according to these revised baseline measurements.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequentcontinuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints.  Except as specified under the Initial 1 treatment restriction, a baseline joint count and ESR and/or CRP should be performed whilst the patient is still on treatment or within 1 month of ceasing prior treatment. Applications under the Initial 1 treatment restriction for new or re-commencing patients must include a joint count and ESR and/or CRP measured at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. |

### Active ankylosing spondylitis

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9455P* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9085E* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel  *8778B* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Active ankylosing spondylitis | | | | | |
| **PBS Indication:** | Active ankylosing spondylitis | | | | | |
| **Treatment phase:** | Initial 1 (new patients *or recommencement of treatment after a break of 5 years or more*) | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist; | | | | | |
| **Clinical criteria:** | The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis;  AND  Patient must not have received any PBS-subsidised treatment *for this condition* with either adalimumab, certolizumab pegol, etanercept, golimumab, infliximab or secukinumab in this treatment cycle;  AND  Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender;  AND  Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months. | | | | | |
| **Population criteria:** | Patient must be ~~an adult~~ *aged 18 years or older.* | | | | | |
| **Prescriber Instructions:** | The application must include details of the NSAIDs trialled, their doses and duration of treatment.  If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.  If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.  If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance.  The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:  (a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND  (b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.  The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.  Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which must include the following:  (i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and  (ii) a completed BASDAI Assessment Form; and  (iii) a completed Exercise Program Self Certification Form included in the supporting information form; and  (iv) a signed patient acknowledgment.  The assessment of the patient's response to the initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted no later than 4 weeks from the cessation of that treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.  A maximum of 16 weeks of treatment with this drug will be approved under this criterion.  Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological disease modifying anti-rheumatic drug (bDMARD) was approved in this cycle and the date of the first application under a new cycle. | | | | | |
| ***Administrative Advice:*** | ***Biosimilar prescribing policy***  *Prescribing of the biosimilar brand Brenzys is encouraged for treatment naïve patients.*  *Encouraging biosimilar prescribing for treatment naïve patients is Government policy. A viable biosimilar market is expected to result in reduced costs for biological medicines, allowing the Government to reinvest in new treatments. Further information can be found on the Biosimilar Awareness Initiative webpage (*[*www.health.gov.au/biosimilars*](http://www.health.gov.au/biosimilars)*).* | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Details of the toxicities, including severity, which will be accepted for the purposes of administering this restriction can be found on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  For details on the appropriate minimum exercise program that will be accepted for the purposes of administering this restriction, please refer to the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au). | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab for adult patients with active ankylosing spondylitis.  Where the term 'bDMARD' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab only.  A patient is eligible for PBS-subsidised treatment with only 1 of the 6 bDMARDs at any 1 time.  Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.  Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent cycle to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of less than 5 years may commence a further course of treatment within the same treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of more than 5 years may commence a new treatment cycle.  There is no limit to the number of treatment cycles a patient may undertake in their lifetime.  (1) How to prescribe PBS-subsidised bDMARD therapy  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 1 for recommencement after 5 years or more and initial 2 for recommencement after a break of less than 5 years).  A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  For second and subsequent courses of PBS-subsidised bDMARD treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment ~~and that~~ ***~~where required~~*** ~~an application is posted~~ *~~submitted~~* ~~to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course~~.  ~~(b) Grandfather patients - secukinumab only.~~  ~~For patients who commenced treatment with secukinumab for ankylosing spondylitis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent. Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction~~  (~~c~~*b*) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  (2) Swapping therapy.  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same treatment cycle.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, ~~within the timeframes specified in the relevant restriction.~~  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and the Department of Human Services will assess response according to these revised baseline measurements.  For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response.  (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.  A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Active ankylosing spondylitis | | | | | |
| **PBS Indication:** | Active ankylosing spondylitis | | | | | |
| **Treatment phase:** | Initial 2 (change or recommencement *of treatment after a break of less than 5 years*).  ~~for all patients treatment~~) | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist; | | | | | |
| **Clinical criteria:** | ~~Patient must have a documented history of active ankylosing spondylitis,~~  ~~AND~~  Patient must have received prior PBS-subsidised biological disease modifying anti-rheumatic drug (bDMARD) treatment for this condition in this treatment cycle;  AND  Patient must not have failed PBS-subsidised therapy with this drug for this condition in the current treatment cycle;  AND  Patient must be eligible to receive further bDMARD therapy. | | | | | |
| **Population criteria:** | Patient must be ~~an adult~~ *aged 18 years or older.* | | | | | |
| **Prescriber Instructions:** | Where the most recent course of PBS-subsidised bDMARDtreatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised bDMARD therapy or, under this restriction, for patients who have received previous PBS-subsidised bDMARD therapy) the patient must have been assessed for response to that course following a minimum of 12 weeks of treatment. These assessments must be provided to the Department of Human Services no later than 4 weeks from the date the course was ceased. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.  Where the most recent course of PBS-subsidised treatment with this drug was approved under the ***first*** continuing ***or subsequent continuing*** treatment criteria, patients must have been assessed for response~~, and the assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.~~  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.  A maximum of 16 weeks of treatment with this drug will be approved under this criterion.  Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was ~~approved~~ ***issued*** in this cycle and the date of the first application under a new cycle. | | | | | |
| **Administrative advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab for adult patients with active ankylosing spondylitis.  Where the term 'bDMARD' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab only.  A patient is eligible for PBS-subsidised treatment with only 1 of the 6 bDMARDs at any 1 time.  Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.  Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent cycle to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of less than 5 years may commence a further course of treatment within the same treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of more than 5 years may commence a new treatment cycle.  There is no limit to the number of treatment cycles a patient may undertake in their lifetime.  (1) How to prescribe PBS-subsidised bDMARD therapy  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 1 for recommencement after 5 years or more and initial 2 for recommencement after a break of less than 5 years).  A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  For second and subsequent courses of PBS-subsidised bDMARD treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment ~~and that~~ ***~~where required~~*** ~~an application is posted~~ *~~submitted~~* ~~to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course~~.  ~~(b) Grandfather patients - secukinumab only.~~  ~~For patients who commenced treatment with secukinumab for ankylosing spondylitis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent. Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction~~  (~~c~~*b*) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  (2) Swapping therapy.  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same treatment cycle.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction.~~  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and the Department of Human Services will assess response according to these revised baseline measurements.  For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.  (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.  A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Active ankylosing spondylitis | | | | | |
| **PBS Indication:** | Active ankylosing spondylitis | | | | | |
| **Treatment phase:** | Initial treatment – Initial 1 (new patients***or recommencement of treatment after a break of 5 years or more***) or Initial 2 (change or recommencement ***of treatment after a break of less than 5 years*** ~~for all patients~~) – balance of supply | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing  Authority Required – Telephone | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist; | | | | | |
| **Clinical criteria:** | ~~Patient must have active, or a documented history of active, ankylosing spondylitis, AND~~  Patient must have received insufficient therapy with this drug ***for this condition*** under the Initial 1 (new patient***or recommencement of treatment after a break of 5 years or more***) restriction to complete 16 weeks treatment;  OR  Patient must have received insufficient therapy with this drug ***for this condition*** under the Initial 2 (change or recommencement ***of treatment after a break of less than 5 years*** ~~for all patients~~) restriction to complete 16 weeks treatment;  AND  The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions. | | | | | |
| **Population criteria:** | Patient must be ~~an adult~~ *aged 18 years or older.* | | | | | |
| **Administrative advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Authority approval for sufficient therapy to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Written application for authority approval for sufficient therapy to complete a maximum of 16 weeks of treatment should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative advice:** | TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab for adult patients with active ankylosing spondylitis.  Where the term 'bDMARD' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab only.  A patient is eligible for PBS-subsidised treatment with only 1 of the 6 bDMARDs at any 1 time.  Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.  Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent cycle to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of less than 5 years may commence a further course of treatment within the same treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of more than 5 years may commence a new treatment cycle.  There is no limit to the number of treatment cycles a patient may undertake in their lifetime.  (1) How to prescribe PBS-subsidised bDMARD therapy  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 1 for recommencement after 5 years or more and initial 2 for recommencement after a break of less than 5 years).  A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  For second and subsequent courses of PBS-subsidised bDMARD treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment ~~and that~~ ***~~where required~~*** ~~an application is posted~~ *~~submitted~~* ~~to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course~~.  ~~(b) Grandfather patients - secukinumab only.~~  ~~For patients who commenced treatment with secukinumab for ankylosing spondylitis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent. Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction~~  (~~c~~*b*) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  (2) Swapping therapy.  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same treatment cycle.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction.~~  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and the Department of Human Services will assess response according to these revised baseline measurements.  For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.  (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.  A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9450Q* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9086F* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *8779C* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Active ankylosing spondylitis | | | | | |
| **PBS Indication:** | Active ankylosing spondylitis | | | | | |
| **Treatment phase:** | ***First*** continuing treatment | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist; | | | | | |
| **Clinical criteria:** | ~~Patient must have a documented history of active ankylosing spondylitis,~~  ~~AND~~  Patient must have received this drug as their most recent course of PBS-subsidised biological disease modifying anti-rheumatic drug (bDMARD) treatment *for this condition* in this treatment cycle,  AND  Patient must have demonstrated an adequate response to treatment with this drug. | | | | | |
| **Population criteria:** | Patient must be ~~an adult~~ *aged 18 years or older.* | | | | | |
| **Prescriber Instructions:** | An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:  (a) an ESR measurement no greater than 25 mm per hour; or  (b) a CRP measurement no greater than 10 mg per L; or  (c) an ESR or CRP measurement reduced by at least 20% from baseline.  Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be ~~measured and supplied in~~ ***used to determine response for*** all subsequent continuing treatment***s*** ~~applications~~.  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.  All measurements provided must be no more than 1 month old at the time of application.  A maximum of 24 weeks of treatment with this drug will be authorised under this criterion.  ~~All applications for continuing treatment with this drug must include a measurement of response to the prior course of therapy. This assessment must be submitted no later than 4 weeks from the cessation of that treatment course~~. ~~If the application is~~ ***~~T~~he*** ~~first~~ application for ***first*** continuing treatment following an initial treatment course ~~it~~ must be made following a minimum of 12 weeks of treatment with this drug. ***This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.***  If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.  Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was ~~approved~~ ***issued*** in this cycle and the date of the first application under a new cycle. | | | | | |
| **Administrative advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826 HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab for adult patients with active ankylosing spondylitis.  Where the term 'bDMARD' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab only.  A patient is eligible for PBS-subsidised treatment with only 1 of the 6 bDMARDs at any 1 time.  Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.  Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent cycle to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of less than 5 years may commence a further course of treatment within the same treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of more than 5 years may commence a new treatment cycle.  There is no limit to the number of treatment cycles a patient may undertake in their lifetime.  (1) How to prescribe PBS-subsidised bDMARD therapy  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 1 for recommencement after 5 years or more and initial 2 for recommencement after a break of less than 5 years).  A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  For second and subsequent courses of PBS-subsidised bDMARD treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment ~~and that~~ ***~~where required~~*** ~~an application is posted~~ *~~submitted~~* ~~to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course~~.  ~~(b) Grandfather patients - secukinumab only.~~  ~~For patients who commenced treatment with secukinumab for ankylosing spondylitis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent. Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction~~  (~~c~~*b*) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  (2) Swapping therapy.  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same treatment cycle.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction.~~  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and the Department of Human Services will assess response according to these revised baseline measurements.  For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.  (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.  A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured. | | | | | |

#### Subsequent continuing restriction – version one. This restriction is used where the subsequent continuing restriction is Authority Required (streamlined)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel | PF |
|  | | | | | | |
| ***Category /***  ***Program*** | *GENERAL – General Schedule (Code GE)* | | | | | |
| ***Prescriber type:*** | *Medical Practitioners* | | | | | |
| ***Condition:*** | *Active ankylosing spondylitis* | | | | | |
| ***PBS Indication:*** | *Active ankylosing spondylitis* | | | | | |
| ***Treatment phase:*** | *Subsequent continuing treatment* | | | | | |
| ***Restriction Level / Method:*** | *Authority Required - Streamlined* | | | | | |
| ***Treatment criteria:*** | *Must be treated by a rheumatologist;* | | | | | |
| ***Clinical criteria:*** | *Patient must have received this drug as their most recent course of PBS-subsidised biological disease modifying anti-rheumatic**drug treatment for this condition in this treatment cycle,*  *AND*  *Patient must have demonstrated an adequate response to treatment with this drug.* | | | | | |
| ***Population criteria:*** | *Patient must be aged 18 years or older.* | | | | | |
| ***Prescriber Instructions:*** | *An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:*  *(a) an ESR measurement no greater than 25 mm per hour; or*  *(b) a CRP measurement no greater than 10 mg per L; or*  *(c) an ESR or CRP measurement reduced by at least 20% from baseline.*  *Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be used to determine response for all subsequent continuing treatments.*  *~~All measurements must be no more than 1 month old at the time the prescription for each continuing treatment is issued.~~*  *A maximum of 24 weeks of treatment with this drug may be prescribed* *under this criterion.*  *The measurement of response to the prior course of therapy must be documented in the patient’s medical notes.*  *Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was issued in this cycle and the date of the first application under a new cycle.* | | | | | |
| ***Administrative advice:*** | *No increase in the maximum quantity or number of units may be authorised.*  *No increase in the maximum number of repeats may be authorised.* | | | | | |
| ***Administrative Advice:*** | TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab for adult patients with active ankylosing spondylitis.  Where the term 'bDMARD' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab only.  A patient is eligible for PBS-subsidised treatment with only 1 of the 6 bDMARDs at any 1 time.  Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.  Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent cycle to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of less than 5 years may commence a further course of treatment within the same treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of more than 5 years may commence a new treatment cycle.  There is no limit to the number of treatment cycles a patient may undertake in their lifetime.  (1) How to prescribe PBS-subsidised bDMARD therapy  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 1 for recommencement after 5 years or more and initial 2 for recommencement after a break of less than 5 years).  A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  For second and subsequent courses of PBS-subsidised bDMARD treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment ~~and that~~ ***~~where required~~*** ~~an application is posted~~ *~~submitted~~* ~~to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course~~.  ~~(b) Grandfather patients - secukinumab only.~~  ~~For patients who commenced treatment with secukinumab for ankylosing spondylitis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent. Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction~~  (~~c~~*b*) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  (2) Swapping therapy.  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same treatment cycle.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and the Department of Human Services will assess response according to these revised baseline measurements.  For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.  (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.  A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured. | | | | | |

#### Subsequent continuing restriction – version two. This restriction is used where the subsequent continuing restriction is Authority Required (in writing).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel | PF |
|  | | | | | | |
| **Category /**  **Program** | *GENERAL – General Schedule (Code GE)* | | | | | |
| **Prescriber type:** | *Medical Practitioners* | | | | | |
| **Condition:** | *Active ankylosing spondylitis* | | | | | |
| **PBS Indication:** | *Active ankylosing spondylitis* | | | | | |
| **Treatment phase:** | *Subsequent continuing treatment* | | | | | |
| **Restriction Level / Method:** | *Authority Required - In Writing* | | | | | |
| **Treatment criteria:** | *Must be treated by a rheumatologist;* | | | | | |
| **Clinical criteria:** | *Patient must have received this drug as their most recent course of PBS-subsidised biological disease modifying anti-rheumatic drug treatment for this condition in this treatment cycle,*  *AND*  *Patient must have demonstrated an adequate response to treatment with this drug.* | | | | | |
| **Population criteria:** | *Patient must be aged 18 years or older.* | | | | | |
| **Prescriber Instructions:** | *An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:*  *(a) an ESR measurement no greater than 25 mm per hour; or*  *(b) a CRP measurement no greater than 10 mg per L; or*  *(c) an ESR or CRP measurement reduced by at least 20% from baseline.*  *Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be used to determine response for all subsequent continuing treatments.*  *The authority application must be made in writing and must include:*  *(a) a completed authority prescription form; and*  *(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.*  *~~All measurements provided must be no more than 1 month old at the time of application.~~*  *A maximum of 24 weeks of treatment with this drug will be authorised under this criterion.*  *Each application for continuing treatment with this drug must include a measurement of response to the prior course of therapy. ~~This assessment must be submitted no later than 4 weeks from the cessation of that treatment course~~. If the response assessment is not submitted ~~within these timeframes~~, the patient will be deemed to have failed this course of treatment.*  *Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised bDMARD was issued in this cycle and the date of the first application under a new cycle.* | | | | | |
| **Administrative advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826 HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab for adult patients with active ankylosing spondylitis.  Where the term 'bDMARD' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab only.  A patient is eligible for PBS-subsidised treatment with only 1 of the 6 bDMARDs at any 1 time.  Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.  Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent cycle to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of less than 5 years may commence a further course of treatment within the same treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of more than 5 years may commence a new treatment cycle.  There is no limit to the number of treatment cycles a patient may undertake in their lifetime.  (1) How to prescribe PBS-subsidised bDMARD therapy  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 1 for recommencement after 5 years or more and initial 2 for recommencement after a break of less than 5 years).  A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  For second and subsequent courses of PBS-subsidised bDMARD treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment ~~and that~~ ***~~where required~~*** ~~an application is posted~~ *~~submitted~~* ~~to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course~~.  ~~(b) Grandfather patients - secukinumab only.~~  ~~For patients who commenced treatment with secukinumab for ankylosing spondylitis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent. Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction~~  (~~c~~*b*) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  (2) Swapping therapy.  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same treatment cycle.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction.~~  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and the Department of Human Services will assess response according to these revised baseline measurements.  For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.  (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.  A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Active ankylosing spondylitis | | | | | |
| **PBS Indication:** | Active ankylosing spondylitis | | | | | |
| **Treatment phase:** | Continuing treatment – balance of supply | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing  Authority Required - Telephone | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist; | | | | | |
| **Clinical criteria:** | ~~Patient must have a documented history of active ankylosing spondylitis,~~  ~~AND~~  Patient must have received insufficient therapy with this drug ***for this condition*** under the ***first c***ontinuing treatment restriction to complete 24 weeks treatment,  ***OR***  ***Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment;***  AND  The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction***s***. | | | | | |
| **Population criteria:** | Patient must be ~~an adult~~ *aged 18 years or older.* | | | | | |
| **Administrative advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Authority approval for sufficient therapy to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Written application for authority approval for sufficient therapy to complete a maximum of 24 weeks of treatment should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative advice:** | TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab for adult patients with active ankylosing spondylitis.  Where the term 'bDMARD' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab only.  A patient is eligible for PBS-subsidised treatment with only 1 of the 6 bDMARDs at any 1 time.  Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.  Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent cycle to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of less than 5 years may commence a further course of treatment within the same treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of more than 5 years may commence a new treatment cycle.  There is no limit to the number of treatment cycles a patient may undertake in their lifetime.  (1) How to prescribe PBS-subsidised bDMARD therapy  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 1 for recommencement after 5 years or more and initial 2 for recommencement after a break of less than 5 years).  A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  For second and subsequent courses of PBS-subsidised bDMARD treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment ~~and that~~ ***~~where required~~*** ~~an application is posted~~ *~~submitted~~* ~~to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course~~.  ~~(b) Grandfather patients - secukinumab only.~~  ~~For patients who commenced treatment with secukinumab for ankylosing spondylitis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent. Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction~~  (~~c~~*b*) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  (2) Swapping therapy.  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same treatment cycle.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and the Department of Human Services will assess response according to these revised baseline measurements.  For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.  (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.  A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured. | | | | | |

## Flow-on changes to restrictions

*The changes to the note associated with the PBS listings for the medicines for the treatment of active ankylosing spondylitis in adults (as below) apply to all other medicines listed for this indication. At the time of the August 2017 PBAC Special meeting this included adalimumab, certolizumab, golimumab, infliximab and secukinumab.*

*The grandfather restriction for secukinumab should be removed at the time the revised note associated with the listings for active ankylosing spondylitis is implemented.*

|  |  |
| --- | --- |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab for adult patients with active ankylosing spondylitis.  Where the term 'bDMARD' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumab only.  A patient is eligible for PBS-subsidised treatment with only 1 of the 6 bDMARDs at any 1 time.  Under these interchangeability arrangements, within a single treatment cycle, a patient may continue to receive long-term treatment with a bDMARD while they continue to show a response to therapy.  Within the same treatment cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised bDMARD more than once.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a treatment cycle and they must have, at a minimum, a 5-year break in PBS-subsidised bDMARD therapy before they are eligible to commence the next cycle. The 5-year break is measured from the date of the last approval for PBS-subsidised bDMARD treatment in the most recent cycle to the date of the first application for initial treatment with a bDMARD under the new treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of less than 5 years may commence a further course of treatment within the same treatment cycle.  A patient who has failed fewer than 3 bDMARDs in a treatment cycle and who has a break in therapy of more than 5 years may commence a new treatment cycle.  There is no limit to the number of treatment cycles a patient may undertake in their lifetime.  (1) How to prescribe PBS-subsidised bDMARD therapy  (a) Initial treatment.  Applications for initial treatment should be made where:  (i) a patient has received no prior PBS-subsidised bDMARD treatment in this treatment cycle and wishes to commence such therapy (Initial 1); or  (ii) a patient has received prior PBS-subsidised (initial or continuing) bDMARD therapy and wishes to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; or  (iii) a patient wishes to re-commence treatment with a specific bDMARD following a break in PBS-subsidised therapy with that agent (Initial 1 for recommencement after 5 years or more and initial 2 for recommencement after a break of less than 5 years).  A patient must be assessed for response to any course of initial PBS-subsidised treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased.  Where a response assessment is not submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that bDMARD.  For second and subsequent courses of PBS-subsidised bDMARD treatment, it is recommended that a patient is reviewed in the month prior to completing their current course of treatment ~~and that~~ ***~~where required~~*** ~~an application is posted~~ *~~submitted~~* ~~to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course~~.  ~~(b) Grandfather patients - secukinumab only.~~  ~~For patients who commenced treatment with secukinumab for ankylosing spondylitis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent. Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction~~  (~~c~~*b*) Continuing treatment.  Following the completion of an initial treatment course with a specific bDMARD, a patient may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. The patient remains eligible to receive continuing bDMARD treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  It is recommended that a patient be reviewed in the month prior to completing their current course of treatment to ensure uninterrupted bDMARD supply.  (2) Swapping therapy.  Once initial treatment with the first PBS-subsidised bDMARD is approved, a patient may swap to an alternate bDMARD within the same treatment cycle without having to requalify with respect to the indices of disease severity (i.e. the erythrocyte sedimentation rate (ESR), the C-reactive protein (CRP) levels and the BASDAI), or the prior NSAID therapy and exercise program requirements.  A patient may trial an alternate bDMARD at any time, regardless of whether they are receiving therapy (initial or continuing) with a bDMARD at the time of the application. However, they cannot swap to a particular bDMARD if they have failed to respond to prior treatment with that drug within the same treatment cycle.  To ensure a patient receives the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, an application for a patient who wishes to swap to an alternate bDMARD should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the bDMARD the patient is ceasing.  (3) Baseline measurements to determine response.  The Department of Human Services will determine whether a response to treatment has been demonstrated based on the baseline measurements of the BASDAI, ESR and/or CRP submitted with the first authority application for a bDMARD.  However, prescribers may provide new baseline measurements any time that an initial treatment authority application is submitted within a treatment cycle and the Department of Human Services will assess response according to these revised baseline measurements.  For a new patient, the BASDAI used to determine the baseline must be measured while the patient is receiving NSAID therapy and completing their exercise program.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequent continuing treatment applications. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be provided to determine response.  (4) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy.  A patient who wishes to trial a second or subsequent treatment cycle following a break in PBS-subsidised bDMARD therapy of at least 5 years, must requalify for initial treatment with respect to the indices of disease severity. Patients must have received treatment with at least 1 NSAID, at an adequate dose, for a minimum of 3 consecutive months immediately prior to the time the BASDAI, ESR and/or CRP levels are measured. |

### Severe psoriatic arthritis

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9457R* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9087G* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel  *9035M* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe psoriatic arthritis | | | | | |
| **PBS Indication:** | Severe psoriatic arthritis | | | | | |
| **Treatment phase:** | Initial 1 (new patient or patient recommencing treatment after a break of 5 years or more) | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist;  OR  Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. | | | | | |
| **Clinical criteria:** | ~~Patient must have severe active psoriatic arthritis,~~  ~~AND~~  Patient must have received no prior PBS-subsidised treatment with a biological agent for this condition;  OR  Patient must have received no PBS-subsidised treatment with a biological agent for at least 5 years if they have previously received PBS-subsidised treatment with a biological agent for this condition,  AND  Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months,  AND  Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months;  OR  Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months,  AND  Patient must not receive more than 16 weeks of treatment under this restriction. | | | | | |
| **Population criteria:** | Patient must be ~~an adult~~ *aged 18 years or older.* | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction 'biological agent' means adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab or ustekinumab.  Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.  Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.  The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:  an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and  either  (a) an active joint count of at least 20 active (swollen and tender) joints; or  (b) at least 4 active joints from the following list of major joints:  (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or  (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).  If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form; and  (3) a signed patient acknowledgement.  *The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to the Department of Human Services no later than 4 weeks from the cessation of the treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.*  *Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this Treatment Cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.* | | | | | |
| **Administrative Advice:** | Details of the toxicities, including severity, which will be accepted as a reason for exempting a patient from the requirement for 3 months treatment with methotrexate and 3 months treatment with sulfasalazine or leflunomide can be found on the Department of Human Services website ([www.humanservices.gov.au](http://www.humanservices.gov.au)). | | | | | |
| **Administrative Advice:** | ~~The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to the Department of Human Services no later than 4 weeks from the cessation of the treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.~~ | | | | | |
| **Administrative Advice:** | ~~Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this Treatment Cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.~~ | | | | | |
| ***Administrative Advice*** | ***Biosimilar prescribing policy***  *Prescribing of the biosimilar brand Brenzys is encouraged for treatment naïve patients.*  *Encouraging biosimilar prescribing for treatment naïve patients is Government policy. A viable biosimilar market is expected to result in reduced costs for biological medicines, allowing the Government to reinvest in new treatments. Further information can be found on the Biosimilar Awareness Initiative webpage (*[*www.health.gov.au/biosimilars*](http://www.health.gov.au/biosimilars)*).* | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab for adult patients with severe active psoriatic arthritis.  Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for psoriatic arthritis are able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction***s*** for each agent.  Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].  The duration of the break in therapy will be measured from the date the last ~~approval~~ ***prescription*** for PBS-subsidised treatment was ***issued*** ~~granted~~ in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.  Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.  Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle ***(initial 2).***  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred~~,~~ ~~and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction,~~ are eligible to commence a new Cycle ***(initial 1).***  There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe active psoriatic arthritis. (1) Initial treatment.  Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 1 or Initial 2).  All applications for initial treatment ~~for non-grandfather patients~~ will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and secukinumab, 18 to 20 weeks of therapy for certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab, and 28 weeks of therapy for ustekinumab. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.  Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.  ~~Grandfather patients - ustekinumab and secukinumab only.~~  ~~For patients who commenced treatment with ustekinumab for psoriatic arthritis prior to 1 May 2016 and for patients who commenced treatment with secukinumab for psoriatic arthritis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.~~  ~~Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.~~  (2) Continuing treatment.  Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to the Department of Human Services ***where applicable***~~no later than 4 weeks from the date that course was ceased~~. Where a response assessment is not submitted, ***where applicable,*** ~~within these timeframes,~~ patients will be deemed to have failed to respond to treatment with that biological agent.  (3) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.  Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.  Within a Treatment Cycle patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; and  (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved~~ authority prescription or remaining repeats for the biological agent the patient is ceasing.  (4) Baseline measurements to determine response.  ~~The Department of Human Services will~~ ***D***etermin~~e~~***ation of*** whether a response to treatment has been demonstrated ***will be*** based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment application is submitted within a treatment Cycle and these revised baseline measurements will be used to assess response.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ***used to determine response*** ~~provided~~for all subsequent continuing treatment***s*** ~~applications~~. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.  (5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years must requalify for initial treatment with respect to both the indices of disease severity. Patients must have ~~received~~ *re-trialled* treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9457R* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9087G* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel  *9035M* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe psoriatic arthritis | | | | | |
| **PBS Indication:** | Severe psoriatic arthritis | | | | | |
| **Treatment phase:** | Initial 2 – (change or recommencement of treatment ***after a break of less than 5 years***) | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist;  OR  Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. | | | | | |
| **Clinical criteria:** | ~~Patient must have a documented history of severe active psoriatic arthritis;~~  ~~AND~~  Patient must have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle;  AND  Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological agents ***for this condition*** within this Treatment Cycle;  AND  Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug ***for this condition*** during the current Treatment Cycle;  AND  Patient must not receive more than 16 weeks of treatment under this restriction. | | | | | |
| **Population criteria:** | Patient must be ~~an adult~~ *aged 18 years or older.* | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction 'biological agent' means adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab or ustekinumab.  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form.  Applications for a patient who has previously received PBS-subsidised treatment with this drug within this Treatment Cycle and who wishes to recommence therapy with this drug within this same Cycle, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised treatment with this drug.  Where the most recent course of PBS-subsidised treatment was approved under either of the initial treatment restrictions (i.e. for patients with no prior PBS-subsidised biological therapy or, under this restriction, for patients who have received previous PBS-subsidised biological therapy ***with this biological agent***), the patient must have been assessed for response following a minimum of 12 weeks of therapy. This assessment must have been submitted ***to the Department of Human Services*** no later than 4 weeks from the date that course was ceased.  Where the most recent course of PBS-subsidised treatment with this drug was ~~approved~~ ***accessed*** under the continuing treatment criteria, the patient must have been assessed for response, and the assessment submitted, ***where applicable to the Department of Human Services.~~,~~*** ~~no later than 4 weeks from the date that course was ceased.~~  ***Where this is the initial course of treatment with a particular biological agent (change of treatment) the assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to the Department of Human Services no later than 4 weeks from the cessation of the treatment course.***  Where a response assessment was not submitted within these timeframes, the patient will be deemed to have failed to respond to treatment.  ***Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this Treatment Cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was issued in this Cycle and the date of the first application under the new Cycle.***  An adequate response to treatment is defined as:  an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and  either of the following:  (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:  (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or  (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). | | | | | |
| **Administrative Advice:** | ~~The assessment of the patient's response to this initial course of treatment must be made following a minimum of 12 weeks of treatment and submitted to the Department of Human Services no later than 4 weeks from the cessation of the treatment course. If the response assessment is not submitted within these timeframes, the patient will be deemed to have failed this course of treatment.~~ | | | | | |
| **Administrative Advice:** | ~~Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this Treatment Cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.~~ | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab for adult patients with severe active psoriatic arthritis.  Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for psoriatic arthritis are able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.  Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].  The duration of the break in therapy will be measured from the date the last ~~approval~~ ***prescription*** for PBS-subsidised treatment was ***issued*** ~~granted~~ in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.  Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.  Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle ***(initial 2).***  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred~~,~~ ~~and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction,~~ are eligible to commence a new Cycle ***(initial 1).***  There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe active psoriatic arthritis. (1) Initial treatment.  Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 1 or Initial 2).  All applications for initial treatment ~~for non-grandfather patients~~ will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and secukinumab, 18 to 20 weeks of therapy for certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab, and 28 weeks of therapy for ustekinumab. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.  Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.  ~~Grandfather patients - ustekinumab and secukinumab only.~~  ~~For patients who commenced treatment with ustekinumab for psoriatic arthritis prior to 1 May 2016 and for patients who commenced treatment with secukinumab for psoriatic arthritis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.~~  ~~Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.~~  (2) Continuing treatment.  Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to the Department of Human Services ***where applicable***~~no later than 4 weeks from the date that course was ceased~~. Where a response assessment is not submitted, ***where applicable,*** ~~within these timeframes~~, patients will be deemed to have failed to respond to treatment with that biological agent.  (3) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.  Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.  Within a Treatment Cycle patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; and  (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved~~ authority prescription or remaining repeats for the biological agent the patient is ceasing.  (4) Baseline measurements to determine response.  ~~The Department of Human Services will~~ ***D***etermin~~e~~***ation of*** whether a response to treatment has been demonstrated ***will be*** based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment application is submitted within a treatment Cycle and these revised baseline measurements will be used to assess response.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ***used to determine response*** ~~provided~~for all subsequent continuing treatment***s*** ~~applications~~. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.  (5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9457R* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9087G* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel  *9035M* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe psoriatic arthritis | | | | | |
| **PBS Indication:** | Severe psoriatic arthritis | | | | | |
| **Treatment phase:** | Initial treatment - Initial 1 (new patient or patient recommencing treatment after a break of 5 years or more) or Initial 2 (change or recommencement of treatment ***after a break of less than 5 years***) - balance of supply. | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing  Authority Required - Telephone | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist;  OR  Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. | | | | | |
| **Clinical criteria:** | Patient must have received insufficient therapy with this drug ***for this condition*** under the Initial 1 (new patient or patient recommencing treatment after a break of 5 years or more) restriction to complete 16 weeks treatment;  OR  Patient must have received insufficient therapy with this drug ***for this condition*** under the Initial 2 (change or recommencement of treatment ***after a break of less than 5 years***) restriction to complete 16 weeks treatment;  AND  The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions. | | | | | |
| **Population criteria:** | Patient must be ~~an adult~~ *aged 18 years or older.* | | | | | |
| **Administrative Advice:** | Authority approval for sufficient therapy to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Written application for authority approval for sufficient therapy to complete a maximum of 16 weeks of treatment should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab for adult patients with severe active psoriatic arthritis.  Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for psoriatic arthritis are able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.  Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].  The duration of the break in therapy will be measured from the date the last ~~approval~~ ***prescription*** for PBS-subsidised treatment was ***issued*** ~~granted~~ in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.  Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.  Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle ***(initial 2).***  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred~~,~~ ~~and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction,~~ are eligible to commence a new Cycle ***(initial 1).***  There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe active psoriatic arthritis. (1) Initial treatment.  Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 1 or Initial 2).  All applications for initial treatment ~~for non-grandfather patients~~ will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and secukinumab, 18 to 20 weeks of therapy for certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab, and 28 weeks of therapy for ustekinumab. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.  Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.  ~~Grandfather patients - ustekinumab and secukinumab only.~~  ~~For patients who commenced treatment with ustekinumab for psoriatic arthritis prior to 1 May 2016 and for patients who commenced treatment with secukinumab for psoriatic arthritis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.~~  ~~Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.~~  (2) Continuing treatment.  Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to the Department of Human Services ***where applicable***~~no later than 4 weeks from the date that course was ceased~~. Where a response assessment is not submitted, ***where applicable,*** ~~within these timeframes~~, patients will be deemed to have failed to respond to treatment with that biological agent.  (3) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.  Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.  Within a Treatment Cycle patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; and  (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved~~ authority prescription or remaining repeats for the biological agent the patient is ceasing.  (4) Baseline measurements to determine response.  ~~The Department of Human Services will~~ ***D***etermin~~e~~***ation of*** whether a response to treatment has been demonstrated ***will be*** based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment application is submitted within a treatment Cycle and these revised baseline measurements will be used to assess response.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ***used to determine response*** ~~provided~~for all subsequent continuing treatment***s*** ~~applications~~. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.  (5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9458T* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9088H* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9036N* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe psoriatic arthritis | | | | | |
| **PBS Indication:** | Severe psoriatic arthritis | | | | | |
| **Treatment phase:** | ***First*** Continuing treatment | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist;  OR  Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. | | | | | |
| **Clinical criteria:** | ~~Patient must have a documented history of severe active psoriatic arthritis;~~  ~~AND~~  Patient must have received this drug as their most recent course of PBS-subsidised treatment with a biological agent for this condition in the current Treatment Cycle;  AND  Patient must demonstrate, at the time of application, an adequate response to treatment with this drug;  AND  Patient must not receive more than 24 weeks of treatment ~~per continuing treatment course authorised~~ under this restriction. | | | | | |
| **Population criteria:** | Patient must be ~~an adult~~ *aged 18 years or older.* | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction 'biological agent' means adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab or ustekinumab.  An adequate response to treatment is defined as:  an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and  either of the following:  (a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or  (b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:  (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or  (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).  The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ~~provided~~ ***used*** for all subsequent continuing treatment***s*** ~~applications~~.  ~~All applications for continuing treatment with this drug must include a measurement of response to the most recent course of PBS-subsidised therapy. This assessment must be submitted no later than 4 weeks from the cessation of that treatment course. If the application is~~ ***~~t~~The*** ~~first~~ application for ***first*** continuing treatment with this drug~~,~~ ~~it~~ must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course. ***This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.***  Where a response assessment is not submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.  ***Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this Treatment Cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was issued in this Cycle and the date of the first application under the new Cycle.***  The authority application must be made in writing and must include:  (1) a completed authority prescription form; and  (2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form. | | | | | |
| **Administrative Advice:** | ~~Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this Treatment Cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.~~ | | | | | |
| **Administrative advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826 HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab for adult patients with severe active psoriatic arthritis.  Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for psoriatic arthritis are able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.  Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].  The duration of the break in therapy will be measured from the date the last ~~approval~~ ***prescription*** for PBS-subsidised treatment was ***issued*** ~~granted~~ in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.  Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.  Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle ***(initial 2).***  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred~~,~~ ~~and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction,~~ are eligible to commence a new Cycle ***(initial 1).***  There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe active psoriatic arthritis. (1) Initial treatment.  Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 1 or Initial 2).  All applications for initial treatment ~~for non-grandfather patients~~ will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and secukinumab, 18 to 20 weeks of therapy for certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab, and 28 weeks of therapy for ustekinumab. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.  Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.  ~~Grandfather patients - ustekinumab and secukinumab only.~~  ~~For patients who commenced treatment with ustekinumab for psoriatic arthritis prior to 1 May 2016 and for patients who commenced treatment with secukinumab for psoriatic arthritis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.~~  ~~Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.~~  (2) Continuing treatment.  Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to the Department of Human Services ***where applicable***~~no later than 4 weeks from the date that course was ceased~~. Where a response assessment is not submitted, ***where applicable,*** ~~within these timeframes,~~ patients will be deemed to have failed to respond to treatment with that biological agent.  (3) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.  Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.  Within a Treatment Cycle patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; and  (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved~~ authority prescription or remaining repeats for the biological agent the patient is ceasing.  (4) Baseline measurements to determine response.  ~~The Department of Human Services will~~ ***D***etermin~~e~~***ation of*** whether a response to treatment has been demonstrated ***will be*** based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment application is submitted within a treatment Cycle and these revised baseline measurements will be used to assess response.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ***used to determine response*** ~~provided~~for all subsequent continuing treatment***s*** ~~applications~~. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.  (5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured. | | | | | |

#### Subsequent continuing restriction – version one. This restriction is used where the subsequent continuing restriction is Authority Required (streamlined)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9458T* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9088H* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9036N* | PF |
|  | | | | | | |
| ***Category /***  ***Program*** | *GENERAL – General Schedule (Code GE)* | | | | | |
| ***Prescriber type:*** | *Medical Practitioners* | | | | | |
| ***Condition:*** | *Severe psoriatic arthritis* | | | | | |
| ***PBS Indication:*** | *Severe psoriatic arthritis* | | | | | |
| ***Treatment phase:*** | *Subsequent continuing treatment* | | | | | |
| ***Restriction Level / Method:*** | *Authority Required - Streamlined* | | | | | |
| ***Treatment criteria:*** | *Must be treated by a rheumatologist;*  *OR*  *Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.* | | | | | |
| ***Clinical criteria:*** | *Patient must have received this drug as their most recent course of PBS-subsidised biological agent**treatment for this condition in this treatment cycle;*  *AND*  *Patient must have demonstrated an adequate response to treatment with this drug.*  *AND*  *Patient must not receive more than 24 weeks of treatment per continuing treatment course under this restriction.* | | | | | |
| ***Population criteria:*** | *Patient must be aged 18 years or older.* | | | | | |
| ***Prescriber Instructions:*** | *For the purposes of this restriction 'biological agent' means adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab or ustekinumab.*  *An adequate response to treatment is defined as:*  *an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and*  *either of the following:*  *(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or*  *(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:*  *(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*  *(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*  *The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.*  *The measurement of response to the prior course of therapy must be documented in the patient’s medical notes.*  *Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was issued in this cycle and the date of the first application under a new cycle.* | | | | | |
| ***Administrative advice:*** | *No increase in the maximum quantity or number of units may be authorised.*  *No increase in the maximum number of repeats may be authorised.* | | | | | |
| ***Administrative advice:*** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab for adult patients with severe active psoriatic arthritis.  Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for psoriatic arthritis are able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.  Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].  The duration of the break in therapy will be measured from the date the last ~~approval~~ ***prescription*** for PBS-subsidised treatment was ***issued*** ~~granted~~ in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.  Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.  Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle ***(initial 2).***  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred~~,~~ ~~and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction,~~ are eligible to commence a new Cycle ***(initial 1).***  There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe active psoriatic arthritis. (1) Initial treatment.  Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 1 or Initial 2).  All applications for initial treatment ~~for non-grandfather patients~~ will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and secukinumab, 18 to 20 weeks of therapy for certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab, and 28 weeks of therapy for ustekinumab. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.  Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.  ~~Grandfather patients - ustekinumab and secukinumab only.~~  ~~For patients who commenced treatment with ustekinumab for psoriatic arthritis prior to 1 May 2016 and for patients who commenced treatment with secukinumab for psoriatic arthritis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.~~  ~~Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.~~  (2) Continuing treatment.  Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to the Department of Human Services ***where applicable***~~no later than 4 weeks from the date that course was ceased~~. Where a response assessment is not submitted, ***where applicable~~,~~*** ~~within these timeframes~~, patients will be deemed to have failed to respond to treatment with that biological agent.  (3) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.  Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.  Within a Treatment Cycle patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; and  (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved~~ authority prescription or remaining repeats for the biological agent the patient is ceasing.  (4) Baseline measurements to determine response.  ~~The Department of Human Services will~~ ***D***etermin~~e~~***ation of*** whether a response to treatment has been demonstrated ***will be*** based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment application is submitted within a treatment Cycle and these revised baseline measurements will be used to assess response.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ***used to determine response*** ~~provided~~for all subsequent continuing treatment***s*** ~~applications~~. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.  (5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured. | | | | | |

#### Subsequent continuing restriction – version two. This restriction is used where the subsequent continuing restriction is Authority Required (in writing).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9458T* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9088H* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9036N* | PF |
|  | | | | | | |
| ***Category /***  ***Program*** | *GENERAL – General Schedule (Code GE)* | | | | | |
| ***Prescriber type:*** | *Medical Practitioners* | | | | | |
| ***Condition:*** | *Severe psoriatic arthritis* | | | | | |
| ***PBS Indication:*** | *Severe psoriatic arthritis* | | | | | |
| ***Treatment phase:*** | *Subsequent continuing treatment* | | | | | |
| ***Restriction Level / Method:*** | *Authority Required - In Writing* | | | | | |
| ***Treatment criteria:*** | *Must be treated by a rheumatologist;*  *OR*  *Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.* | | | | | |
| ***Clinical criteria:*** | *Patient must have received this drug as their most recent course of PBS-subsidised biological agent**treatment for this condition in this treatment cycle,*  *AND*  *Patient must have demonstrated an adequate response to treatment with this drug.* | | | | | |
| ***Population criteria:*** | *Patient must be aged 18 years or older.* | | | | | |
| ***Prescriber Instructions:*** | *For the purposes of this restriction 'biological agent' means adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab or ustekinumab.*  *An adequate response to treatment is defined as:*  *an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and*  *either of the following:*  *(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or*  *(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:*  *(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or*  *(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).*  *The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.*  *Each application for continuing treatment with this drug must include a measurement of response to the most recent course of PBS-subsidised therapy. Where a response assessment is not submitted the patient will be deemed to have failed to respond to treatment with this drug.*  *Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this Treatment Cycle. Patients may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological agent was issued in this Cycle and the date of the first application under the new Cycle.*  *The authority application must be made in writing and must include:*  *(1) a completed authority prescription form; and*  *(2) a completed Psoriatic Arthritis PBS Authority Application - Supporting Information Form.* | | | | | |
| **Administrative Advice:** | *No increase in the maximum quantity or number of units may be authorised.*  *No increase in the maximum number of repeats may be authorised.* | | | | | |
| **Administrative Advice:** | *Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*  *Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at* [*www.humanservices.gov.au*](http://www.humanservices.gov.au)*.*  *Applications for authority to prescribe should be forwarded to:*  *Department of Human Services*  *Complex Drugs*  *Reply Paid 9826 HOBART TAS 7001* | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab for adult patients with severe active psoriatic arthritis.  Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for psoriatic arthritis are able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.  Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].  The duration of the break in therapy will be measured from the date the last ~~approval~~ ***prescription*** for PBS-subsidised treatment was ***issued*** ~~granted~~ in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.  Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.  Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle ***(initial 2).***  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred~~,~~ ~~and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction,~~ are eligible to commence a new Cycle ***(initial 1).***  There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe active psoriatic arthritis. (1) Initial treatment.  Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 1 or Initial 2).  All applications for initial treatment ~~for non-grandfather patients~~ will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and secukinumab, 18 to 20 weeks of therapy for certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab, and 28 weeks of therapy for ustekinumab. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.  Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.  ~~Grandfather patients - ustekinumab and secukinumab only.~~  ~~For patients who commenced treatment with ustekinumab for psoriatic arthritis prior to 1 May 2016 and for patients who commenced treatment with secukinumab for psoriatic arthritis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.~~  ~~Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.~~  (2) Continuing treatment.  Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to the Department of Human Services ***where applicable***~~no later than 4 weeks from the date that course was ceased~~. Where a response assessment is not submitted, ***where applicable,*** ~~within these timeframes,~~ patients will be deemed to have failed to respond to treatment with that biological agent.  (3) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.  Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.  Within a Treatment Cycle patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; and  (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved~~ authority prescription or remaining repeats for the biological agent the patient is ceasing.  (4) Baseline measurements to determine response.  ~~The Department of Human Services will~~ ***D***etermin~~e~~***ation of*** whether a response to treatment has been demonstrated ***will be*** based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment application is submitted within a treatment Cycle and these revised baseline measurements will be used to assess response.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ***used to determine response*** ~~provided~~for all subsequent continuing treatment***s*** ~~applications~~. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.  (5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9458T* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9088H* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9036N* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe psoriatic arthritis | | | | | |
| **PBS Indication:** | Severe psoriatic arthritis | | | | | |
| **Treatment phase:** | Continuing treatment – Balance of Supply | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing  Authority Required - Telephone | | | | | |
| **Treatment criteria:** | Must be treated by a rheumatologist;  OR  Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis. | | | | | |
| **Clinical criteria:** | Patient must have received insufficient therapy with this drug ***for this condition*** under the ***first*** Continuing treatment restriction to complete 24 weeks treatment;  ***OR***  ***Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment;***  AND  The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction***s***. | | | | | |
| **Population criteria:** | Patient must be ~~an adult~~ *aged 18 years or older.* | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Authority approval for sufficient therapy to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Written application for authority approval for sufficient therapy to complete a maximum of 24 weeks of treatment should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab for adult patients with severe active psoriatic arthritis.  Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for psoriatic arthritis are able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.  Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].  The duration of the break in therapy will be measured from the date the last ~~approval~~ ***prescription*** for PBS-subsidised treatment was ***issued*** ~~granted~~ in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.  Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.  Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle ***(initial 2).***  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred~~,~~ ~~and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction,~~ are eligible to commence a new Cycle ***(initial 1).***  There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe active psoriatic arthritis. (1) Initial treatment.  Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 1 or Initial 2).  All applications for initial treatment ~~for non-grandfather patients~~ will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and secukinumab, 18 to 20 weeks of therapy for certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab, and 28 weeks of therapy for ustekinumab. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.  Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.  ~~Grandfather patients - ustekinumab and secukinumab only.~~  ~~For patients who commenced treatment with ustekinumab for psoriatic arthritis prior to 1 May 2016 and for patients who commenced treatment with secukinumab for psoriatic arthritis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.~~  ~~Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.~~  (2) Continuing treatment.  Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to the Department of Human Services ***where applicable***~~no later than 4 weeks from the date that course was ceased~~. Where a response assessment is not submitted, ***where applicable,*** ~~within these timeframes,~~ patients will be deemed to have failed to respond to treatment with that biological agent.  (3) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.  Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.  Within a Treatment Cycle patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; and  (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved~~ authority prescription or remaining repeats for the biological agent the patient is ceasing.  (4) Baseline measurements to determine response.  ~~The Department of Human Services will~~ ***D***etermin~~e~~***ation of*** whether a response to treatment has been demonstrated ***will be*** based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment application is submitted within a treatment Cycle and these revised baseline measurements will be used to assess response.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ***used to determine response*** ~~provided~~for all subsequent continuing treatment***s*** ~~applications~~. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.  (5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured. | | | | | |

## Flow-on changes to restrictions

*The changes to the note associated with the PBS listings for the medicines for the treatment of severe psoriatic arthritis in adults (as below) apply to all other medicines listed for this indication. At the time of the August 2017 PBAC Special meeting this included adalimumab, certolizumab, golimumab, infliximab, secukinumab and ustekinumab.*

*The grandfather restrictions for ustekinumab and secukinumab should be removed at the time the revised note associated with the listings for severe psoriatic arthritis is implemented.*

|  |  |
| --- | --- |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE PSORIATIC ARTHRITIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab for adult patients with severe active psoriatic arthritis.  Patients are eligible for PBS-subsidised treatment with only 1 of the above biological agents at any 1 time.  Where the term 'biological agents' appears in notes and restrictions, it refers  to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for psoriatic arthritis are able to commence a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to experience a disease flare when swapping to the alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Following demonstration of response to initial treatment, these biological agents are available under the PBS for continuing treatment as set out in the continuing treatment restriction for each agent.  Once patients have either failed or ceased to sustain a response to treatment 3 times, they are deemed to have completed a single Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological therapy before they are eligible to commence another Cycle [further details are under '(5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy' below].  The duration of the break in therapy will be measured from the date the last ~~approval~~ ***prescription*** for PBS-subsidised treatment was ***issued*** ~~granted~~ in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Cycle.  Within the same Cycle, patients are not allowed to fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for any biological agent, they must change to an alternate agent which they have not previously failed, if they wish to continue PBS-subsidised biological treatment.  Patients for whom a break in PBS-subsidised therapy of less than 5 years has occurred, and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle ***(initial 2).***  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred~~,~~ ~~and, who have failed therapy fewer than 3 times within a particular treatment Cycle, as defined in the relevant restriction,~~ are eligible to commence a new Cycle ***(initial 1).***  There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe active psoriatic arthritis. (1) Initial treatment.  Applications for initial treatment should be made where:  (i) patients have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); and  (ii) patients have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under 'Swapping therapy' below]; and  (iii) patients wish to re-commence treatment with a specific biological agent following a break in PBS-subsidised therapy with that specific agent (Initial 1 or Initial 2).  All applications for initial treatment ~~for non-grandfather patients~~ will be limited to provide for a maximum of 16 weeks of therapy for adalimumab, etanercept and golimumab and secukinumab, 18 to 20 weeks of therapy for certolizumab pegol (depending upon the dosing regimen), 22 weeks of therapy for infliximab, and 28 weeks of therapy for ustekinumab. It is recommended that patients be reviewed in the month prior to completing their course of initial treatment to ensure uninterrupted biological agent supply.  Patients must be assessed for response to any course of PBS-subsidised initial treatment following a minimum of 12 weeks of therapy and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. Where a response assessment is not submitted within these timeframes, patients will be deemed to have failed to respond to treatment with that biological agent.  ~~Grandfather patients - ustekinumab and secukinumab only.~~  ~~For patients who commenced treatment with ustekinumab for psoriatic arthritis prior to 1 May 2016 and for patients who commenced treatment with secukinumab for psoriatic arthritis prior to 1 October 2016, applications for initial PBS-subsidised treatment as continuing therapy may be made under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with any biological agent prior to PBS listing of that agent.~~  ~~Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment for all agents. Approval will be based on the criteria included in the relevant restriction.~~  (2) Continuing treatment.  Following the completion of an initial treatment course with a specific biological agent, patients may qualify to receive up to 24 weeks of continuing treatment with that drug providing they have demonstrated an adequate response to treatment. Patients are eligible to receive continuing biological treatment with the same drug in courses of up to 24 weeks providing they continue to sustain the response.  Patients must be assessed for response to a course of continuing therapy, and the assessment must be submitted to the Department of Human Services ***where applicable***~~no later than 4 weeks from the date that course was ceased~~. Where a response assessment is not submitted, ***where applicable,*** ~~within these timeframes,~~ patients will be deemed to have failed to respond to treatment with that biological agent.  (3) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate biological agent without having to re-qualify with respect to either the indices of disease severity (i.e. erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level, and active joint count) or the prior non-biological therapy requirements.  Patients may swap to an alternate biological agent at any time, regardless of whether they are receiving therapy (initial or continuing) with a biological agent at the time of the application or not.  Within a Treatment Cycle patients may alternate between therapy with any biological agent of their choice (1 at a time) providing:  (i) they have not received PBS-subsidised treatment with that particular biological agent previously; or  (ii) they have demonstrated an adequate response to that particular biological agent if they have previously trialled it on the PBS; and  (iii) they have not previously failed to respond to treatment 3 times in this Treatment Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved~~, within the timeframes specified in the relevant restriction.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved~~ authority prescription or remaining repeats for the biological agent the patient is ceasing.  (4) Baseline measurements to determine response.  ~~The Department of Human Services will~~ ***D***etermin~~e~~***ation of*** whether a response to treatment has been demonstrated ***will be*** based on the baseline measurements of the indices of disease severity submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment application is submitted within a treatment Cycle and these revised baseline measurements will be used to assess response.  To ensure consistency in determining response, the same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be ***used to determine response*** ~~provided~~for all subsequent continuing treatment***s*** ~~applications~~. Therefore, where only an ESR or CRP level is provided at baseline, an ESR or CRP level respectively must be ~~provided~~ ***used*** to determine response. Similarly, where the baseline active joint count is based on total active joints (i.e. 20 or more active joints), response will be determined according to a reduction in the total number of active joints.  (5) Re-commencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent treatment Cycle following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment with respect to both the indices of disease severity. Patients must have received treatment with methotrexate and sulfasalazine or leflunomide, at an adequate dose, for a minimum of 3 months at the time the ESR or CRP levels and the active joint counts are measured. |

### Severe chronic plaque psoriasis

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9461Y* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9091L* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel  *9037P* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe chronic plaque psoriasis | | | | | |
| **PBS Indication:** | Severe chronic plaque psoriasis | | | | | |
| **Treatment phase:** | Initial 1 - Whole body (new patient (no prior biological agent) or patient recommencing treatment after a break of 5 years or more) | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a dermatologist | | | | | |
| **Clinical criteria:** | Patient must have severe chronic plaque psoriasis where lesions have been present for at least 6 months from the time of initial diagnosis,  AND  Patient must not have received any prior PBS-subsidised treatment with a biological agent for this condition;  OR  Patient must not have received PBS-subsidised treatment with a biological agent for at least 5 years, if they have previously received PBS-subsidised treatment with a biological agent for this condition and wish to commence a new Treatment Cycle,  AND  Patient must have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments: (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks,  AND  Patient must have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (whole body),  AND  The treatment must be as systemic monotherapy (other than methotrexate),  AND  Patient must not receive more than 16 weeks of treatment under this restriction. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction 'biological agent' means adalimumab, etanercept, infliximab, ixekizumab, secukinumab or ustekinumab.  Where treatment with methotrexate, cyclosporin or acitretin is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, details must be provided at the time of application.  Where intolerance to treatment with phototherapy, methotrexate, cyclosporin or acitretin developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.  The following criterion indicates failure to achieve an adequate response to prior treatment and must be demonstrated in the patient at the time of the application:  (a) A current Psoriasis Area and Severity Index (PASI) score of greater than 15, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment.  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements. | | | | | |
| ***Administrative Advice*** | ***Biosimilar prescribing policy***  *Prescribing of the biosimilar brand Brenzys is encouraged for treatment naïve patients.*  *Encouraging biosimilar prescribing for treatment naïve patients is Government policy. A viable biosimilar market is expected to result in reduced costs for biological medicines, allowing the Government to reinvest in new treatments. Further information can be found on the Biosimilar Awareness Initiative webpage (*[*www.health.gov.au/biosimilars*](http://www.health.gov.au/biosimilars)*).* | | | | | |
| **Administrative Advice:** | Details of the toxicities, including severity, which will be accepted as a reason for exempting a patient from the requirement for 6 weeks treatment with phototherapy, methotrexate, cyclosporin or acitretin can be found on the Department of Human Services website ([www.humanservices.gov.au](http://www.humanservices.gov.au)). | | | | | |
| **Administrative Advice:** | A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss. | | | | | |
| **Administrative Advice:** | It is recommended that an application is ~~posted~~ ***submitted*** to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised treatment with this drug. | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.  Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  ~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~  Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.  Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:  There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.  (1) Application for approval for initial treatment.  Applications for a course of initial treatment should be made in the following situations:  (i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or  (iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or  (iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).  All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.  Grandfather patients (ixekizumab only).  Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.  Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.  (2) Assessment of response to initial treatment.  When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.  The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.  (3) Application for continuing treatment.  Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.  For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where applicable*** an application is ~~posted~~ ***submitted*** to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~ ***where*** ***required***, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~ ***~~where required~~*** ~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~  (4) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.  (5) Baseline measurements to determine response.  ~~The Department of Human Services will determine whether a~~ Response to treatment ***will be determined*** ~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.  To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.  (6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9461Y* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9091L* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel  *9037P* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe chronic plaque psoriasis | | | | | |
| **PBS Indication:** | Severe chronic plaque psoriasis | | | | | |
| **Treatment phase:** | Initial 2 - Whole body (change or recommencement of treatment after a break of less than 5 years) | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a dermatologist | | | | | |
| **Clinical criteria:** | Patient must have a documented history of severe chronic plaque psoriasis,  AND  Patient must have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle,  AND  Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological agents for this condition within this Treatment Cycle,  AND  Patient must not have failed, or ceased to respond to, PBS-subsidised therapy with this drug for the treatment of this condition in the current Treatment Cycle,  AND  The treatment must be as systemic monotherapy (other than methotrexate),  AND  Patient must not receive more than 16 weeks of treatment under this restriction | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction 'biological agent' means adalimumab, etanercept, infliximab, ixekizumab, secukinumab or ustekinumab.  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets including the dates of assessment of the patient's condition; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.  Applications for patients who have demonstrated a response to PBS-subsidised treatment with this drug within this Treatment Cycle and who wish to recommence treatment with this drug within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised treatment with this drug has been submitted ~~within 1 month of cessation of treatment~~.  An adequate response to treatment is defined as:  A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the prebiological treatment baseline value for this Treatment Cycle. | | | | | |
| **Administrative Advice:** | A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss. | | | | | |
| **Administrative Advice:** | It is recommended that an application is ~~posted~~ ***submitted*** to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised treatment with this drug. | | | | | |
| **Administrative Advice:** | Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may recommence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle. | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.  Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  ~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~  Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.  Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:  There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.  (1) Application for approval for initial treatment.  Applications for a course of initial treatment should be made in the following situations:  (i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or  (iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or  (iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).  All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.  Grandfather patients (ixekizumab only).  Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.  Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.  (2) Assessment of response to initial treatment.  When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.  The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.  (3) Application for continuing treatment.  Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.  For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where applicable*** an application is ~~posted~~ ***submitted*** to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~ ***where*** ***required***, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~ ***~~where required~~*** ~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~  (4) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.  (5) Baseline measurements to determine response.  ~~The Department of Human Services will determine whether a~~ Response to treatment ***will be determined*** ~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.  To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.  (6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9461Y* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9091L* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel  *9037P* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe chronic plaque psoriasis | | | | | |
| **PBS Indication:** | Severe chronic plaque psoriasis | | | | | |
| **Treatment phase:** | Initial 1 - Face, hand, foot (new patient (no prior biological agent) or patient recommencing treatment after a break of 5 years or more) | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a dermatologist | | | | | |
| **Clinical criteria:** | Patient must have severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis,  AND  Patient must not have received any prior PBS-subsidised treatment with a biological agent for this condition;  OR  Patient must not have received PBS-subsidised treatment with a biological agent for at least 5 years, if they have previously received PBS-subsidised treatment with a biological agent for this condition and wish to commence a new Treatment Cycle,  AND  Patient must have failed to achieve an adequate response, as demonstrated by a Psoriasis Area and Severity Index (PASI) assessment, to at least 3 of the following 4 treatments: (i) phototherapy (UVB or PUVA) for 3 treatments per week for at least 6 weeks; and/or (ii) methotrexate at a dose of at least 10 mg weekly for at least 6 weeks; and/or (iii) cyclosporin at a dose of at least 2 mg per kg per day for at least 6 weeks; and/or (iv) acitretin at a dose of at least 0.4 mg per kg per day for at least 6 weeks,  AND  Patient must have signed a patient and prescriber acknowledgement indicating they understand and acknowledge that PBS-subsidised treatment will cease if they do not meet the predetermined response criterion for ongoing PBS-subsidised treatment, as outlined in the restriction for continuing treatment (face, hand, foot),  AND  The treatment must be as systemic monotherapy (other than methotrexate),  AND  Patient must not receive more than 16 weeks of treatment under this restriction. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction 'biological agent' means adalimumab, etanercept, infliximab, ixekizumab, secukinumab or ustekinumab.  Where treatment with methotrexate, cyclosporin or acitretin is contraindicated according to the relevant TGA-approved Product Information, or where phototherapy is contraindicated, details must be provided at the time of application.  Where intolerance to treatment with phototherapy, methotrexate, cyclosporin or acitretin developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.  The following criterion indicates failure to achieve an adequate response to prior treatment and must be demonstrated in the patient at the time of the application:  (a) Chronic plaque psoriasis classified as severe due to a plaque or plaques on the face, palm of a hand or sole of a foot where:  (i) at least 2 of the 3 Psoriasis Area and Severity Index (PASI) symptom subscores for erythema, thickness and scaling are rated as severe or very severe, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment; or  (ii) the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed, preferably whilst still on treatment, but no longer than 1 month following cessation of the most recent prior treatment;  (b) A PASI assessment must be completed for each prior treatment course, preferably whilst still on treatment, but no longer than 1 month following cessation of each course of treatment.  (c) The most recent PASI assessment must be no more than 1 month old at the time of application.  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the following:  (i) the completed current and previous Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition; and  (ii) details of previous phototherapy and systemic drug therapy [dosage (where applicable), date of commencement and duration of therapy]; and  (iii) the signed patient and prescriber acknowledgements. | | | | | |
| ***Administrative Advice*** | ***Biosimilar prescribing policy***  *Prescribing of the biosimilar brand Brenzys is encouraged for treatment naïve patients.*  *Encouraging biosimilar prescribing for treatment naïve patients is Government policy. A viable biosimilar market is expected to result in reduced costs for biological medicines, allowing the Government to reinvest in new treatments. Further information can be found on the Biosimilar Awareness Initiative webpage (*[*www.health.gov.au/biosimilars*](http://www.health.gov.au/biosimilars)*).* | | | | | |
| **Administrative Advice:** | Details of the toxicities, including severity, which will be accepted as a reason for exempting a patient from the requirement for 6 weeks treatment with phototherapy, methotrexate, cyclosporin or acitretin can be found on the Department of Human Services website ([www.humanservices.gov.au](http://www.humanservices.gov.au)). | | | | | |
| **Administrative Advice:** | A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.  Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss. | | | | | |
| **Administrative Advice:** | It is recommended that an application is ~~posted~~ ***submitted*** to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised treatment with this drug. | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.  Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  ~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~  Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.  Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:  There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.  (1) Application for approval for initial treatment.  Applications for a course of initial treatment should be made in the following situations:  (i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or  (iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or  (iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).  All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.  Grandfather patients (ixekizumab only).  Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.  Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.  (2) Assessment of response to initial treatment.  When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.  The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.  (3) Application for continuing treatment.  Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.  For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where applicable*** an application is ~~posted~~ ***submitted*** to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~ ***where*** ***required***, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~ ***~~where required~~*** ~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~  (4) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.  (5) Baseline measurements to determine response.  ~~The Department of Human Services will determine whether a~~ Response to treatment ***will be determined*** ~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.  To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.  (6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9461Y* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9091L* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel  *9037P* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe chronic plaque psoriasis | | | | | |
| **PBS Indication:** | Severe chronic plaque psoriasis | | | | | |
| **Treatment phase:** | Initial 2 - Face, hand, foot (change or recommencement of treatment after a break of less than 5 years) | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a dermatologist | | | | | |
| **Clinical criteria:** | Patient must have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot,  AND  Patient must have received prior PBS-subsidised treatment with a biological agent for this condition in this Treatment Cycle,  AND  Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological agents for this condition within this Treatment Cycle,  AND  Patient must not have failed, or ceased to respond to, PBS-subsidised therapy with this drug for the treatment of this condition in the current Treatment Cycle,  AND  The treatment must be as systemic monotherapy (other than methotrexate),  AND  Patient must not receive more than 16 weeks of treatment under this restriction. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction 'biological agent' means adalimumab, etanercept, infliximab, ixekizumab, secukinumab or ustekinumab.  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the following:  (i) the completed current Psoriasis Area and Severity Index (PASI) calculation sheets and face, hand, foot area diagrams including the dates of assessment of the patient's condition; and  (ii) details of prior biological treatment, including dosage, date and duration of treatment.  Applications for patients who have demonstrated a response to PBS-subsidised treatment with this drug within this Treatment Cycle and who wish to recommence treatment with this drug within the same Cycle following a break in therapy, will only be approved where evidence of the patient's response to their most recent course of PBS-subsidised treatment with this drug has been submitted ~~within 1 month of cessation of treatment~~.  An adequate response to treatment is defined as the plaque or plaques assessed prior to biological treatment showing:  (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or  (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value. | | | | | |
| **Administrative Advice:** | A PASI assessment of the patient's response to this initial course of treatment must be made after at least 12 weeks of treatment so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss. | | | | | |
| **Administrative Advice:** | It is recommended that an application is ~~posted~~ ***submitted*** to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised treatment with this drug. | | | | | |
| **Administrative Advice:** | Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may recommence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle. | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.  Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  ~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~  Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.  Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:  There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.  (1) Application for approval for initial treatment.  Applications for a course of initial treatment should be made in the following situations:  (i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or  (iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or  (iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).  All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.  Grandfather patients (ixekizumab only).  Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.  Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.  (2) Assessment of response to initial treatment.  When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.  The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.  (3) Application for continuing treatment.  Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.  For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where applicable*** an application is ~~posted~~ ***submitted*** to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~ ***where*** ***required***, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~ ***~~where required~~*** ~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~  (4) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.  (5) Baseline measurements to determine response.  ~~The Department of Human Services will determine whether a~~ Response to treatment ***will be determined*** ~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.  To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.  (6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9461Y* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 3 |  | Brenzys  Enbrel  *9091L* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 3 |  | Enbrel  *9037P* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe chronic plaque psoriasis | | | | | |
| **PBS Indication:** | Severe chronic plaque psoriasis | | | | | |
| **Treatment phase:** | Initial 1, Whole body or Face, hand, foot (new patient or patient recommencing treatment after a break of 5 years or more) or Initial 2, Whole body or Face, hand, foot (change or recommencement of treatment after a break of less than 5 years) - balance of supply | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing  Authority Required - Telephone | | | | | |
| **Treatment criteria:** | Must be treated by a dermatologist | | | | | |
| **Clinical criteria:** | Patient must have received insufficient therapy with this drug ***for this condition*** under the Initial 1, Whole body (new patient or patient recommencing treatment after a break of 5 years or more) restriction to complete 16 weeks treatment;  OR  Patient must have received insufficient therapy with this drug ***for this condition*** under the Initial 2, Whole body (change or recommencement of treatment after a break of less than 5 years ) restriction to complete 16 weeks treatment;  OR  Patient must have received insufficient therapy with this drug ***for this condition*** under the Initial 1, Face, hand, foot (new patient or patient recommencing treatment after a break of 5 years or more) restriction to complete 16 weeks treatment;  OR  Patient must have received insufficient therapy with this drug ***for this condition*** under the Initial 2, Face, hand, foot (change or recommencement of treatment after a break of less than 5 years) restriction to complete 16 weeks treatment,  AND  The treatment must be as systemic monotherapy (other than methotrexate),  AND  The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Administrative Advice:** | Authority approval for sufficient therapy to complete a maximum of 16 weeks of treatment may be requested by telephone by contacting the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday). | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.  Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  ~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~  Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.  Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:  There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.  (1) Application for approval for initial treatment.  Applications for a course of initial treatment should be made in the following situations:  (i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or  (iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or  (iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).  All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.  Grandfather patients (ixekizumab only).  Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.  Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.  (2) Assessment of response to initial treatment.  When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.  The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.  (3) Application for continuing treatment.  Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.  For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where applicable*** an application is ~~posted~~ ***submitted*** to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~ ***where*** ***required***, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~ ***~~where required~~*** ~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~  (4) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.  (5) Baseline measurements to determine response.  ~~The Department of Human Services will determine whether a~~ Response to treatment ***will be determined*** ~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.  To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.  (6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9462B* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9431J* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9429G* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe chronic plaque psoriasis | | | | | |
| **PBS Indication:** | Severe chronic plaque psoriasis | | | | | |
| **Treatment phase:** | ***First*** Continuing treatment, whole body | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a dermatologist | | | | | |
| **Clinical criteria:** | Patient must have a documented history of severe chronic plaque psoriasis,  AND  Patient must have received this drug as their most recent course of PBS-subsidised treatment with a biological agent for this condition in the current Treatment Cycle,  AND  Patient must have demonstrated an adequate response to their most recent course of treatment with this drug,  AND  The treatment must be as systemic monotherapy (other than methotrexate),  AND  Patient must not receive more than 24 weeks of treatment ~~per continuing treatment course authorised~~ under this restriction. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction 'biological agent' means adalimumab, etanercept, infliximab, ixekizumab, secukinumab or ustekinumab.  An adequate response to treatment is defined as:  A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the prebiological treatment baseline value for this Treatment Cycle.  ~~All applications for continuing treatment with this drug must include a measurement of response to the most recent course of PBS-subsidised therapy. This assessment must be submitted no later than 4 weeks from the cessation of that treatment course. If the application is~~ ***~~tT~~he*** ~~first~~ application for ***first*** continuing treatment with this drug, ~~it~~ must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course. ***This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.***  Where a response assessment is not submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet including the date of the assessment of the patient's condition.  The most recent PASI assessment must be no more than 1 month old at the time of application.  Approval will be based on the PASI assessment of response to the most recent course of treatment with this drug. | | | | | |
| **Administrative Advice:** | A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for ~~further~~ continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss. | | | | | |
| **Administrative Advice:** | It is recommended that an application is ~~posted~~ ***submitted*** to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised treatment with this drug. | | | | | |
| **Administrative Advice:** | Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may recommence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle. | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.  Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  ~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~  Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.  Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:  There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.  (1) Application for approval for initial treatment.  Applications for a course of initial treatment should be made in the following situations:  (i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or  (iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or  (iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).  All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.  Grandfather patients (ixekizumab only).  Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.  Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.  (2) Assessment of response to initial treatment.  When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.  The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.  (3) Application for continuing treatment.  Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.  For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where applicable*** an application is ~~posted~~ ***submitted*** to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~ ***where*** ***required***, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~ ***~~where required~~*** ~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~  (4) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.  (5) Baseline measurements to determine response.  ~~The Department of Human Services will determine whether a~~ Response to treatment ***will be determined*** ~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.  To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.  (6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9462B* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9431J* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9429G* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe chronic plaque psoriasis | | | | | |
| **PBS Indication:** | Severe chronic plaque psoriasis | | | | | |
| **Treatment phase:** | ***First*** Continuing treatment, face, hand, foot | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing | | | | | |
| **Treatment criteria:** | Must be treated by a dermatologist | | | | | |
| **Clinical criteria:** | Patient must have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot,  AND  Patient must have received this drug as their most recent course of PBS-subsidised treatment with a biological agent for this condition in the current Treatment Cycle,  AND  Patient must have demonstrated an adequate response to their most recent course of treatment with this drug,  AND  The treatment must be as systemic monotherapy (other than methotrexate),  AND  Patient must not receive more than 24 weeks of treatment ~~per continuing treatment course authorised~~ under this restriction. | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Prescriber Instructions:** | For the purposes of this restriction 'biological agent' means adalimumab, etanercept, infliximab, ixekizumab, secukinumab or ustekinumab.  An adequate response to treatment is defined as the plaque or plaques assessed prior to biological treatment showing:  (i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or  (ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.  ~~All applications for continuing treatment with this drug must include a measurement of response to the most recent course of PBS-subsidised therapy. This assessment must be submitted no later than 4 weeks from the cessation of that treatment course. If the application is~~ ***~~t~~The*** ~~first~~ application for ***first*** continuing treatment with this drug, ~~it~~ must be accompanied by an assessment of response to a minimum of 12 weeks of treatment with the initial treatment course. ***This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.***  Where a response assessment is not submitted within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.  The authority application must be made in writing and must include:  (a) a completed authority prescription form; and  (b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the following:  (i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams including the date of the assessment of the patient's condition.  The most recent PASI assessment must be no more than 1 month old at the time of application.  Approval will be based on the PASI assessment of response to the most recent course of treatment with this drug.  The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline. | | | | | |
| **Administrative Advice:** | A PASI assessment of the patient's response must be conducted within 4 weeks prior to completion of this course of treatment. This assessment, which will be used to determine eligibility for ~~further~~ continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this course of treatment. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.  In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss. | | | | | |
| **Administrative Advice:** | It is recommended that an application is ~~posted~~ ***submitted*** to the Department of Human Services no later than 2 weeks prior to the patient completing their current treatment course to ensure continuity of treatment for those patients who meet the continuation criterion for PBS-subsidised treatment with this drug. | | | | | |
| **Administrative Advice:** | Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may recommence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle. | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.  Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  ~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~  Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.  Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:  There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.  (1) Application for approval for initial treatment.  Applications for a course of initial treatment should be made in the following situations:  (i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or  (iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or  (iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).  All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.  Grandfather patients (ixekizumab only).  Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.  Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.  (2) Assessment of response to initial treatment.  When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.  The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.  (3) Application for continuing treatment.  Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.  For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where applicable*** an application is ~~posted~~ ***submitted*** to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~ ***where*** ***required***, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~ ***~~where required~~*** ~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~  (4) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.  (5) Baseline measurements to determine response.  ~~The Department of Human Services will determine whether a~~ Response to treatment ***will be determined*** ~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.  To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.  (6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application. | | | | | |
| **Administrative Advice:** | Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at [www.humanservices.gov.au](http://www.humanservices.gov.au).  Applications for authority to prescribe should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |

#### Subsequent continuing restriction – version one. This restriction is used where the subsequent continuing restriction is Authority Required (streamlined)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9462B* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9431J* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9429G* | PF |
|  | | | | | | |
| ***Category /***  ***Program*** | *GENERAL – General Schedule (Code GE)* | | | | | |
| ***Prescriber type:*** | *Medical Practitioners* | | | | | |
| ***Condition:*** | *Severe chronic plaque psoriasis* | | | | | |
| ***PBS Indication:*** | *Severe chronic plaque psoriasis* | | | | | |
| ***Treatment phase:*** | ***Subsequent*** *Continuing treatment, whole body* | | | | | |
| ***Restriction Level / Method:*** | *Authority Required - Streamlined* | | | | | |
| ***Treatment criteria:*** | *Must be treated by a dermatologist* | | | | | |
| ***Clinical criteria:*** | *Patient must have a documented history of severe chronic plaque psoriasis,*  *AND*  *Patient must have received this drug as their most recent course of PBS-subsidised treatment with a biological agent for this condition in the current Treatment Cycle,*  *AND*  *Patient must have demonstrated an adequate response to their most recent course of treatment with this drug,*  *AND*  *The treatment must be as systemic monotherapy (other than methotrexate),*  *AND*  *Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course under this restriction.* | | | | | |
| ***Population criteria:*** | *Patient must be aged 18 years or older.* | | | | | |
| ***Prescriber Instructions:*** | *For the purposes of this restriction 'biological agent' means adalimumab, etanercept, infliximab, ixekizumab, secukinumab or ustekinumab.*  *An adequate response to treatment is defined as:*  *A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the prebiological treatment baseline value for this Treatment Cycle.*  *The measurement of response to the prior course of therapy must be documented in the patient’s medical notes.*  *Determination of response must be based on the PASI assessment of response to the most recent course of treatment with this drug.*  *Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.*  *Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may recommence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.* | | | | | |
| ***Administrative Advice:*** | *No increase in the maximum quantity or number of units may be authorised.*  *No increase in the maximum number of repeats may be authorised.* | | | | | |
| ***Administrative Advice:*** | *TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS*  *The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.*  *Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.*  *Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.*  *Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.*  *~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~*  *Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.*  *Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.*  *Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.*  *Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.*  *How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:*  *There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.*  *(1) Application for approval for initial treatment.*  *Applications for a course of initial treatment should be made in the following situations:*  *(i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or*  *(ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or*  *(iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or*  *(iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).*  *All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.*  *Grandfather patients (ixekizumab only).*  *Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.*  *Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.*  *(2) Assessment of response to initial treatment.*  *When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.*  *The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*  *(3) Application for continuing treatment.*  *Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.*  *For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that* ***where applicable*** *an application is ~~posted~~* ***submitted*** *to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~* ***where******required****, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~* ***~~where required~~*** *~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~*  *(4) Swapping therapy.*  *Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.*  *Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.*  *Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.*  *To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.*  *To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.*  *(5) Baseline measurements to determine response.*  *~~The Department of Human Services will determine whether a~~ Response to treatment* ***will be determined*** *~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.*  *To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.*  *(6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.* | | | | | |
| ***Administrative Advice:*** | *Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*  *Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at* [*www.humanservices.gov.au*](http://www.humanservices.gov.au)*.*  *Applications for authority to prescribe should be forwarded to:*  *Department of Human Services*  *Complex Drugs*  *Reply Paid 9826*  *HOBART TAS 7001* | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9462B* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9431J* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9429G* | PF |
|  | | | | | | |
| ***Category /***  ***Program*** | *GENERAL – General Schedule (Code GE)* | | | | | |
| ***Prescriber type:*** | *Medical Practitioners* | | | | | |
| ***Condition:*** | *Severe chronic plaque psoriasis* | | | | | |
| ***PBS Indication:*** | *Severe chronic plaque psoriasis* | | | | | |
| ***Treatment phase:*** | ***Subsequent*** *Continuing treatment, face, hand, foot* | | | | | |
| ***Restriction Level / Method:*** | *Authority Required - Streamlined* | | | | | |
| ***Treatment criteria:*** | *Must be treated by a dermatologist* | | | | | |
| ***Clinical criteria:*** | *Patient must have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot,*  *AND*  *Patient must have received this drug as their most recent course of PBS-subsidised treatment with a biological agent for this condition in the current Treatment Cycle,*  *AND*  *Patient must have demonstrated an adequate response to their most recent course of treatment with this drug,*  *AND*  *The treatment must be as systemic monotherapy (other than methotrexate),*  *AND*  *Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course under this restriction.* | | | | | |
| ***Population criteria:*** | *Patient must be aged 18 years or older.* | | | | | |
| ***Prescriber Instructions:*** | *For the purposes of this restriction 'biological agent' means adalimumab, etanercept, infliximab, ixekizumab, secukinumab or ustekinumab.*  *An adequate response to treatment is defined as the plaque or plaques assessed prior to biological treatment showing:*  *(i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or*  *(ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.*  *The measurement of response to the prior course of therapy must be documented in the patient’s medical notes.*  *Determination of response must be based on the PASI assessment of response to the most recent course of treatment with this drug.*  *The PASI assessment for continuing treatment must be performed on the same affected area assessed at baseline.*  *Patients who fail to demonstrate a response to treatment with this drug under this restriction will not be eligible to receive further PBS-subsidised treatment with this drug in this treatment cycle.*  *Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may recommence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.* | | | | | |
| ***Administrative Advice:*** | *No increase in the maximum quantity or number of units may be authorised.*  *No increase in the maximum number of repeats may be authorised.* | | | | | |
| ***Administrative Advice:*** | *TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS*  *The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.*  *Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.*  *Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.*  *Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.*  *~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~*  *Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.*  *Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.*  *Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.*  *Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.*  *How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:*  *There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.*  *(1) Application for approval for initial treatment.*  *Applications for a course of initial treatment should be made in the following situations:*  *(i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or*  *(ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or*  *(iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or*  *(iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).*  *All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.*  *Grandfather patients (ixekizumab only).*  *Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.*  *Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.*  *(2) Assessment of response to initial treatment.*  *When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.*  *The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*  *(3) Application for continuing treatment.*  *Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.*  *For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that* ***where applicable*** *an application is ~~posted~~* ***submitted*** *to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~* ***where******required****, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~* ***~~where required~~*** *~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~*  *(4) Swapping therapy.*  *Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.*  *Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.*  *Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.*  *To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.*  *To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.*  *(5) Baseline measurements to determine response.*  *~~The Department of Human Services will determine whether a~~ Response to treatment* ***will be determined*** *~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.*  *To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.*  *(6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.* | | | | | |
| ***Administrative Advice:*** | *Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*  *Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at* [*www.humanservices.gov.au*](http://www.humanservices.gov.au)*.*  *Applications for authority to prescribe should be forwarded to:*  *Department of Human Services*  *Complex Drugs*  *Reply Paid 9826*  *HOBART TAS 7001* | | | | | |

#### Subsequent continuing restriction – version two. This restriction is used where the subsequent continuing restriction is Authority Required (in writing).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9462B* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9431J* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9429G* | PF |
|  | | | | | | |
| ***Category /***  ***Program*** | *GENERAL – General Schedule (Code GE)* | | | | | |
| ***Prescriber type:*** | *Medical Practitioners* | | | | | |
| ***Condition:*** | *Severe chronic plaque psoriasis* | | | | | |
| ***PBS Indication:*** | *Severe chronic plaque psoriasis* | | | | | |
| ***Treatment phase:*** | *Subsequent continuing treatment, whole body* | | | | | |
| ***Restriction Level / Method:*** | *Authority Required - In Writing* | | | | | |
| ***Treatment criteria:*** | *Must be treated by a dermatologist* | | | | | |
| ***Clinical criteria:*** | *Patient must have a documented history of severe chronic plaque psoriasis,*  *AND*  *Patient must have received this drug as their most recent course of PBS-subsidised treatment with a biological agent for this condition in the current Treatment Cycle,*  *AND*  *Patient must have demonstrated an adequate response to their most recent course of treatment with this drug,*  *AND*  *The treatment must be as systemic monotherapy (other than methotrexate),*  *AND*  *Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction.* | | | | | |
| ***Population criteria:*** | *Patient must be aged 18 years or older.* | | | | | |
| ***Prescriber Instructions:*** | *For the purposes of this restriction 'biological agent' means adalimumab, etanercept, infliximab, ixekizumab, secukinumab or ustekinumab.*  *An adequate response to treatment is defined as:*  *A Psoriasis Area and Severity Index (PASI) score which is reduced by 75% or more, or is sustained at this level, when compared with the prebiological treatment baseline value for this Treatment Cycle.*  *Each application for continuing treatment with this drug must include a measurement of response to the most recent course of PBS-subsidised therapy. ~~This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.~~*  *Where a response assessment is not submitted ~~within these timeframes~~, the patient will be deemed to have failed to respond to treatment with this drug.*  *Approval will be based on the PASI assessment of response to the most recent course of treatment with this drug.*  *The authority application must be made in writing and must include:*  *(a) a completed authority prescription form; and*  *(b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the following:*  *(i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet including the date of the assessment of the patient's condition.*  *~~The most recent PASI assessment must be no more than 1 month old at the time of application.~~*  *Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may recommence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.* | | | | | |
| ***Administrative Advice:*** | *No increase in the maximum quantity or number of units may be authorised.*  *No increase in the maximum number of repeats may be authorised.* | | | | | |
| ***Administrative Advice:*** | *TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS*  *The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.*  *Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.*  *Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.*  *Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.*  *~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~*  *Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.*  *Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.*  *Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.*  *Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.*  *How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:*  *There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.*  *(1) Application for approval for initial treatment.*  *Applications for a course of initial treatment should be made in the following situations:*  *(i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or*  *(ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or*  *(iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or*  *(iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).*  *All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.*  *Grandfather patients (ixekizumab only).*  *Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.*  *Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.*  *(2) Assessment of response to initial treatment.*  *When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.*  *The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*  *(3) Application for continuing treatment.*  *Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.*  *For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that* ***where applicable*** *an application is ~~posted~~* ***submitted*** *to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~* ***where******required****, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~* ***~~where required~~*** *~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~*  *(4) Swapping therapy.*  *Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.*  *Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.*  *Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.*  *To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.*  *To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.*  *(5) Baseline measurements to determine response.*  *~~The Department of Human Services will determine whether a~~ Response to treatment* ***will be determined*** *~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.*  *To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.*  *(6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.* | | | | | |
| ***Administrative Advice:*** | *Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*  *Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at* [*www.humanservices.gov.au*](http://www.humanservices.gov.au)*.*  *Applications for authority to prescribe should be forwarded to:*  *Department of Human Services*  *Complex Drugs*  *Reply Paid 9826*  *HOBART TAS 7001* | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9462B* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9431J* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9429G* | PF |
|  | | | | | | |
| ***Category /***  ***Program*** | *GENERAL – General Schedule (Code GE)* | | | | | |
| ***Prescriber type:*** | *Medical Practitioners* | | | | | |
| ***Condition:*** | *Severe chronic plaque psoriasis* | | | | | |
| ***PBS Indication:*** | *Severe chronic plaque psoriasis* | | | | | |
| ***Treatment phase:*** | *Subsequent continuing treatment, face, hand, foot* | | | | | |
| ***Restriction Level / Method:*** | *Authority Required - In Writing* | | | | | |
| ***Treatment criteria:*** | *Must be treated by a dermatologist* | | | | | |
| ***Clinical criteria:*** | *Patient must have a documented history of severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot,*  *AND*  *Patient must have received this drug as their most recent course of PBS-subsidised treatment with a biological agent for this condition in the current Treatment Cycle,*  *AND*  *Patient must have demonstrated an adequate response to their most recent course of treatment with this drug,*  *AND*  *The treatment must be as systemic monotherapy (other than methotrexate),*  *AND*  *Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction.* | | | | | |
| ***Population criteria:*** | *Patient must be aged 18 years or older.* | | | | | |
| ***Prescriber Instructions:*** | *For the purposes of this restriction 'biological agent' means adalimumab, etanercept, infliximab, ixekizumab, secukinumab or ustekinumab.*  *An adequate response to treatment is defined as the plaque or plaques assessed prior to biological treatment showing:*  *(i) a reduction in the Psoriasis Area and Severity Index (PASI) symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the pre-biological treatment baseline values; or*  *(ii) a reduction by 75% or more in the skin area affected, or sustained at this level, as compared to the pre-biological treatment baseline value.*  *Each application for continuing treatment with this drug must include a measurement of response to the most recent course of PBS-subsidised therapy. ~~This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.~~*  *Where a response assessment is not submitted ~~within these timeframes~~, the patient will be deemed to have failed to respond to treatment with this drug.*  *Approval will be based on the PASI assessment of response to the most recent course of treatment with this drug.*  *The authority application must be made in writing and must include:*  *(a) a completed authority prescription form; and*  *(b) a completed Severe Chronic Plaque Psoriasis PBS Authority Application - Supporting Information Form which includes the following:*  *(i) the completed Psoriasis Area and Severity Index (PASI) calculation sheet and face, hand, foot area diagrams including the date of the assessment of the patient's condition.*  *~~The most recent PASI assessment must be no more than 1 month old at the time of application.~~*  *Patients who fail to demonstrate a response to treatment with 3 biological agents are deemed to have completed this Treatment Cycle and must cease PBS-subsidised therapy. These patients may recommence a new Biological Treatment Cycle after a minimum of 5 years has elapsed between the date the last prescription for a PBS-subsidised biological agent was approved in this Cycle and the date of the first application under the new Cycle.* | | | | | |
| ***Administrative Advice:*** | *No increase in the maximum quantity or number of units may be authorised.*  *No increase in the maximum number of repeats may be authorised.* | | | | | |
| ***Administrative Advice:*** | *TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS*  *The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.*  *Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.*  *Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.*  *Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.*  *~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~*  *Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.*  *Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.*  *Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.*  *Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.*  *How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:*  *There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.*  *(1) Application for approval for initial treatment.*  *Applications for a course of initial treatment should be made in the following situations:*  *(i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or*  *(ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or*  *(iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or*  *(iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).*  *All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.*  *Grandfather patients (ixekizumab only).*  *Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.*  *Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.*  *(2) Assessment of response to initial treatment.*  *When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.*  *The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.*  *(3) Application for continuing treatment.*  *Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.*  *For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that* ***where applicable*** *an application is ~~posted~~* ***submitted*** *to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~* ***where******required****, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~* ***~~where required~~*** *~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~*  *(4) Swapping therapy.*  *Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.*  *Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.*  *Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.*  *To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.*  *To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.*  *(5) Baseline measurements to determine response.*  *~~The Department of Human Services will determine whether a~~ Response to treatment* ***will be determined*** *~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.*  *To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.*  *(6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application.* | | | | | |
| ***Administrative Advice:*** | *Any queries concerning the arrangements to prescribe may be directed to the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).*  *Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Department of Human Services website at* [*www.humanservices.gov.au*](http://www.humanservices.gov.au)*.*  *Applications for authority to prescribe should be forwarded to:*  *Department of Human Services*  *Complex Drugs*  *Reply Paid 9826*  *HOBART TAS 7001* | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Name, Restriction,  Manner of administration and form | | Max.  Qty | №.of  Rpts |  | Proprietary Name and Manufacturer  *Item code* | |
| ETANERCEPT  Injection 50 mg in 1 mL single use auto-injector, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9462B* | MK  PF |
| ETANERCEPT  Injection 50 mg in 1 mL single use pre-filled syringe, 4, 1 | | 1 | 5 |  | Brenzys  Enbrel  *9431J* | MK  PF |
| ETANERCEPT  Injection 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack | | 2 | 5 |  | Enbrel  *9429G* | PF |
|  | | | | | | |
| **Category /**  **Program** | GENERAL – General Schedule (Code GE) | | | | | |
| **Prescriber type:** | Medical Practitioners | | | | | |
| **Condition:** | Severe chronic plaque psoriasis | | | | | |
| **PBS Indication:** | Severe chronic plaque psoriasis | | | | | |
| **Treatment phase:** | Continuing treatment Whole body or Continuing treatment, Face, hand, foot - balance of supply | | | | | |
| **Restriction Level / Method:** | Authority Required - In Writing  Authority Required - Telephone | | | | | |
| **Treatment criteria:** | Must be treated by a dermatologist | | | | | |
| **Clinical criteria:** | Patient must have received insufficient therapy with this drug under the ***first*** Continuing treatment, Whole body restriction to complete 24 weeks treatment;  OR  Patient must have received insufficient therapy with this drug under the ***first*** Continuing treatment, Face, hand, foot restriction to complete 24 weeks treatment,  ***OR***  ***Patient must have received insufficient therapy with this drug under the subsequent continuing treatment Authority Required (in writing), Whole body restriction to complete 24 weeks treatment;***  ***OR***  ***Patient must have received insufficient therapy with this drug under the subsequent continuing treatment Authority Required (in writing), Face, hand, foot restriction to complete 24 weeks treatment,***  AND  The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions,  AND  The treatment must be as systemic monotherapy (other than methotrexate). | | | | | |
| **Population criteria:** | Patient must be aged 18 years or older. | | | | | |
| **Administrative Advice:** | No increase in the maximum quantity or number of units may be authorised.  No increase in the maximum number of repeats may be authorised. | | | | | |
| **Administrative Advice:** | Authority approval for sufficient therapy to complete a maximum of 24 weeks of treatment may be requested by telephone by contacting the Department of Human Services on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. EST Monday to Friday).  Written application for authority approval for sufficient therapy to complete a maximum of 24 weeks of treatment should be forwarded to:  Department of Human Services  Complex Drugs  Reply Paid 9826  HOBART TAS 7001 | | | | | |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.  Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  ~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~  Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.  Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:  There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.  (1) Application for approval for initial treatment.  Applications for a course of initial treatment should be made in the following situations:  (i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or  (iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or  (iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).  All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.  Grandfather patients (ixekizumab only).  Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.  Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.  (2) Assessment of response to initial treatment.  When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.  The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.  (3) Application for continuing treatment.  Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.  For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where applicable*** an application is ~~posted~~ ***submitted*** to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~ ***where*** ***required***, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~ ***~~where required~~*** ~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~  (4) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.  (5) Baseline measurements to determine response.  ~~The Department of Human Services will determine whether a~~ Response to treatment ***will be determined*** ~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.  To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.  (6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application. | | | | | |

## Flow-on changes to restrictions

*The changes to the note associated with the PBS listings for the medicines for the treatment of severe chronic plaque psoriasis in adults (as below) apply to all other medicines listed for this indication. At the time of the August 2017 PBAC Special meeting this included adalimumab, infliximab, secukinumab, ixekizumab and ustekinumab.*

|  |  |
| --- | --- |
| **Administrative Advice:** | TREATMENT OF ADULT PATIENTS WITH SEVERE CHRONIC PLAQUE PSORIASIS  The following information applies to the prescribing under the Pharmaceutical Benefits Scheme (PBS) of the biological agents adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab for adult patients with severe chronic plaque psoriasis. Therefore, where the term 'biological agents' appears in notes and restrictions, it refers to adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab only.  Patients receiving PBS-subsidised treatment for chronic plaque psoriasis are deemed to have commenced a 'Biological Treatment Cycle' (Cycle), where they may trial biological agents without having to meet the initial treatment criteria, that is they will not need to experience a disease flare, when swapping to an alternate agent. Under these interchangeability arrangements, within a single Cycle, patients may receive long-term treatment with a biological agent as long as they sustain a response to therapy.  Patients are eligible for PBS-subsidised treatment with only 1 biological agent at any 1 time.  Within the same Treatment Cycle, a patient cannot trial and fail, or cease to respond to, the same PBS-subsidised biological agent more than once. Therefore once a patient fails to meet the response criteria for a PBS-subsidised biological agent, they must change to an alternate agent if they wish to continue PBS-subsidised biological treatment.  ~~A patient still in their first Treatment Cycle who, prior to 1 December 2007, under the interchangeability arrangements in effect at the time, was authorised to receive PBS-subsidised initial treatment for chronic plaque psoriasis with the same agent twice is exempt from this condition in respect of applications approved prior to 1 December 2007.~~  Patients must be assessed for response to each course of treatment according to the criteria included in the relevant continuing treatment restriction.  Once a patient has either failed or ceased to respond to treatment 3 times, they are deemed to have completed a Treatment Cycle and they must have, at a minimum, a 5-year break in PBS-subsidised biological agent therapy before they are eligible to commence the next Cycle. The duration of the break in therapy is measured from the date of the last approval for PBS-subsidised biological agent treatment in the most recent Cycle to the date of the first application for initial treatment with a biological agent under the new Treatment Cycle.  Patients for whom a break in PBS-subsidised therapy of less than 5 years duration has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, may commence a further course of treatment within that Cycle.  Patients for whom a break in PBS-subsidised therapy of 5 years or more has occurred, and, who have failed therapy fewer than 3 times within a particular Cycle, as defined in the relevant restriction, are eligible to commence a new Cycle. There is no limit to the number of Biological Treatment Cycles a patient may undertake in their lifetime.  How to prescribe biological agents for the treatment of severe chronic plaque psoriasis:  There are separate restrictions for both the initial and continuing treatment for psoriasis affecting the whole body, versus psoriasis affecting the face, hands and feet.  (1) Application for approval for initial treatment.  Applications for a course of initial treatment should be made in the following situations:  (i) patients who have received no prior PBS-subsidised biological treatment and wish to commence such therapy (Initial 1); or  (ii) patients who wish to recommence treatment following a break of 5 years or more and commence a new treatment cycle (Initial 1); or  (iii) patients who have received prior PBS-subsidised biological therapy and wish to trial an alternate agent (Initial 2) [further details are under '(4) Swapping therapy' below]; or  (iv) patients who wish to recommence treatment following a break of less than 5 years in PBS-subsidised therapy with that agent (Initial 2).  All applications for initial treatment for non-grandfather patients will be limited to provide for a maximum of 16 weeks of treatment of adalimumab, etanercept, ixekizumab and secukinumab, 22 weeks of treatment of infliximab and 28 weeks of treatment of ustekinumab.  Grandfather patients (ixekizumab only).  Applications for patients who commenced treatment with ixekizumab for chronic plaque psoriasis prior to 1 February 2017 may be made for initial PBS-subsidised treatment as continuing therapy under the relevant initial treatment restriction (Initial 3). These patients access the PBS interchangeability arrangements in the same way as new patients who have not been treated with a biological agent prior to PBS listing of that agent.  Applications for initial PBS-subsidised treatment for grandfather patients will provide for a maximum of 24 weeks of treatment. Approval will be based on the criteria included in the relevant restriction.  (2) Assessment of response to initial treatment.  When prescribing initial treatment with a biological agent, a PASI assessment must be conducted after at least 12 weeks of treatment. This assessment must be submitted to the Department of Human Services within 1 month of the completion of this initial treatment course. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with that biological agent. In circumstances where it is not possible to submit a response assessment within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.  The PASI assessment for continuing treatment must be performed on the same affected area as assessed at baseline.  (3) Application for continuing treatment.  Following the completion of an initial treatment course with a biological agent to which an adequate response has been demonstrated, patients may qualify to receive up to 24 weeks of continuing treatment with that biological agent. Patients are eligible to continue to receive continuous treatment with 24 week courses providing they continue to sustain a response.  For second and subsequent courses of PBS-subsidised treatment with a specific biological agent it is recommended that a patient is reviewed in the month prior to completing their current course of treatment and that ***where applicable*** an application is ~~posted~~ ***submitted*** to the Department of Human Services ~~no later than 2 weeks prior to the patient completing their current treatment course~~. Where a response assessment is not submitted to the Department of Human Services ~~within these timeframes~~ ***where*** ***required***, patients will be deemed to have failed to sustain a response to treatment with that biological agent. ~~In circumstances where it is not possible to submit a response assessment~~ ***~~where required~~*** ~~within these timeframes, please call the Department of Human Services on 1800 700 270 to discuss.~~  (4) Swapping therapy.  Once an authority for initial treatment with the first PBS-subsidised biological agent is approved, patients may swap to an alternate agent within the same Treatment Cycle without having to requalify with respect to disease severity (i.e. a PASI score of greater than 15), or prior treatment requirements.  Patients who are not able to complete a minimum of 12 weeks of an initial treatment course will be deemed to have failed treatment with that agent.  Patients may trial an alternate biological agent at any time, regardless of whether they are receiving therapy with a biological agent at the time of the application or not. However, they cannot swap to a particular agent if they have failed to respond to treatment with that particular agent within the same Cycle.  To ensure patients receive the maximum treatment opportunities allowed under the interchangeability arrangements, it is important that they are assessed for response to every course of treatment ~~approved, within the timeframes specified in the relevant restriction~~.  To avoid confusion, applications for patients who wish to swap to an alternate biological agent should be accompanied by the ~~approved authority~~ prescription or remaining repeats for the agent being ceased.  (5) Baseline measurements to determine response.  ~~The Department of Human Services will determine whether a~~ Response to treatment ***will be determined*** ~~has been demonstrated,~~ based on the baseline PASI assessment submitted with the first authority application for a biological agent. However, prescribers may provide new baseline measurements any time that an initial treatment authority is submitted within a Treatment Cycle and subsequent response will be assessed according to this revised PASI score.  To ensure consistency in determining response, the same body area assessed at the baseline PASI assessment must be assessed for demonstration of response to treatment for the purposes of all continuing treatment ~~application~~s.  (6) Recommencement of treatment after a 5-year break in PBS-subsidised therapy. Patients who wish to trial a second or subsequent Biological Treatment Cycle, following a break in PBS-subsidised biological therapy of at least 5 years, must requalify for initial treatment according to the criteria of the relevant restriction and index of disease severity. Patients must have had at least 1 prior treatment, as listed in the criteria, for a minimum of 6 weeks, and must have a PASI assessment conducted preferably whilst still on treatment, but no later than 1 month following cessation of treatment. The PASI assessment must be no older than 1 month at the time of application. |

1. Context for Decision

The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

1. Sponsor’s Comment

The sponsor had no comment.